

(A joint stock limited company)

Company



Contents

CONTENTS	2
FOREWORD	4
1. INTRODUCTION	5
2. SCOPE OF THE STUDY	31
3. RESEARCH METHODS	41
4. RESEARCH RESULTS	45
5. CONCLUSIONS	49
6. REFERENCES	52
7. APPENDICES	54
8. INDEX	57
9. GLOSSARY	59
10. ABBREVIATIONS	61
11. NOTES	63
DEFINITIONS	151





Corporate Information

Board of Directors

Executive Directors

- . G A 王 (Chairman)
- . A G 王 强
- . A G 王 强

Non-executive Directors

- . I H 王
- . I C 王

Independent Non-executive Directors

- . H G 王
- . JI 王 强
- . CHA 王 强 王 强

Supervisory Board

- . H G 王 (Chairman)
- . I C 王
- . JI 王 强

- . CHA 王 强 王 强 (Chairman)
- . G A 王
- . JI 王 强

Supervisory Board

- . JI 王 强 (Chairman)
- . H G 王
- . CHA 王 强 王 强

Supervisory Board

- . G A 王 (Chairman)
- . H G 王
- . I H 王

Supervisory Board

- . 王 强 (Chairman)
- . 王 强
- . HA G 王
- . IE 王
- . IA C 王 王 王

Supervisory Board

- . A G 王
- . G 王 强

Supervisory Board

- . G A 王
- . G 王 强

Supervisory Board

BD C 王 强 王 强 C 王 强 王 强 A 王 强

Supervisory Board

C 王 强

Supervisory Board

H 王 强 王 强 C 王 强 王 强 D 王 强

Corporate Information

40/F, D
248
H
F
C
E
H
H
C
1712-1716, 17
H
C
133
E
H
C
2120
C
I
: (86) 577 3377 1639
F : (86) 577 3373 9117
E : @



附注

截至 2024 年 6 月 30 日止期间

	For the six months ended June 30,	
	2024	2023
	(RMB' 000)	(B'000)
	(Unaudited)	(未经审计)
流动资产	828,957	777,925
非流动资产	61,513	60,207
资产总计	16,516	11,473
流动负债	44,996	43,729
非流动负债	50,724	43,750
负债总计	-5,727	4,979
所有者权益	116,536	113,591

	As at	
	June 30, 2024	A
	(RMB' 000)	(B'000)
	(Unaudited)	(未经审计)
流动资产	3,008,352	3,047,637
非流动资产	1,581,890	1,639,431
资产总计	1,426,462	1,403,206
流动负债	1,290,906	1,265,065
非流动负债	135,555	143,141

Management Discussion and Analysis

B I E E I E A D

Figure 1: Schematic diagram of the proposed framework. The framework is designed to process input data (represented by a grid of colored dots) and generate output results (represented by a grid of colored dots). The process involves several stages: Input Data, Feature Extraction, and Output Results. The input data is processed through a series of operations (represented by arrows and labels like G, C, F) to produce the final output results. The diagram illustrates the flow of information and the transformation of data throughout the framework.

I

G 2024, G B329.0 6.6%

A 5.1% B765.6

G 15.9% C B50.7

32 (D 31, 2023: 32), H), 11,648 (D 31, 2023: 11,263).

Psychiatric Healthcare Business

$G \cong$



Management Discussion and Analysis

2024 年 1 月 15 日，本公司召開 2024 年第一次股東大會，審議通過了《關於 2023 年度利潤分配方案的決議》，擬以 2023 年 12 月 31 日末公司總股本 100,000,000 股為基数，向全體股東派發現金紅利，每股派發 0.1 元（含稅），共計派發現金紅利 10,000,000.00 元。該方案尚需經 2024 年第二次股東大會審議通過後方可實施。

2024 年 1 月 15 日，本公司召開 2024 年第一次股東大會，審議通過了《關於 2023 年度利潤分配方案的決議》，擬以 2023 年 12 月 31 日末公司總股本 100,000,000 股為基数，向全體股東派發現金紅利，每股派發 0.1 元（含稅），共計派發現金紅利 10,000,000.00 元。該方案尚需經 2024 年第二次股東大會審議通過後方可實施。

2024 年 1 月 15 日，本公司召開 2024 年第一次股東大會，審議通過了《關於 2023 年度利潤分配方案的決議》，擬以 2023 年 12 月 31 日末公司總股本 100,000,000 股為基数，向全體股東派發現金紅利，每股派發 0.1 元（含稅），共計派發現金紅利 10,000,000.00 元。該方案尚需經 2024 年第二次股東大會審議通過後方可實施。

2024 年 1 月 15 日，本公司召開 2024 年第一次股東大會，審議通過了《關於 2023 年度利潤分配方案的決議》，擬以 2023 年 12 月 31 日末公司總股本 100,000,000 股為基数，向全體股東派發現金紅利，每股派發 0.1 元（含稅），共計派發現金紅利 10,000,000.00 元。該方案尚需經 2024 年第二次股東大會審議通過後方可實施。

Elderly Healthcare Business

A. 根據《國務院辦公廳關於發展銀髮經濟增進老年人福祉的意見》（國辦發〔2024〕1 號），2024 年 1 月 15 日，國務院辦公廳印發了《關於發展銀髮經濟增進老年人福祉的意見》，明確了發展銀髮經濟的總體要求和主要任務。根據《意見》，到 2024 年底，全國銀髮經濟發展水平將有顯著提高，老年人福祉將進一步增進。

B. 根據《國務院辦公廳關於發展銀髮經濟增進老年人福祉的意見》（國辦發〔2024〕1 號），2024 年 1 月 15 日，國務院辦公廳印發了《關於發展銀髮經濟增進老年人福祉的意見》，明確了發展銀髮經濟的總體要求和主要任務。根據《意見》，到 2024 年底，全國銀髮經濟發展水平將有顯著提高，老年人福祉將進一步增進。

C. 根據《國務院辦公廳關於發展銀髮經濟增進老年人福祉的意見》（國辦發〔2024〕1 號），2024 年 1 月 15 日，國務院辦公廳印發了《關於發展銀髮經濟增進老年人福祉的意見》，明確了發展銀髮經濟的總體要求和主要任務。根據《意見》，到 2024 年底，全國銀髮經濟發展水平將有顯著提高，老年人福祉將進一步增進。

D. 根據《國務院辦公廳關於發展銀髮經濟增進老年人福祉的意見》（國辦發〔2024〕1 號），2024 年 1 月 15 日，國務院辦公廳印發了《關於發展銀髮經濟增進老年人福祉的意見》，明確了發展銀髮經濟的總體要求和主要任務。根據《意見》，到 2024 年底，全國銀髮經濟發展水平將有顯著提高，老年人福祉將進一步增進。

E. 根據《國務院辦公廳關於發展銀髮經濟增進老年人福祉的意見》（國辦發〔2024〕1 號），2024 年 1 月 15 日，國務院辦公廳印發了《關於發展銀髮經濟增進老年人福祉的意見》，明確了發展銀髮經濟的總體要求和主要任務。根據《意見》，到 2024 年底，全國銀髮經濟發展水平將有顯著提高，老年人福祉將進一步增進。

Management Discussion and Analysis

I 2024, G 2,730 31.1% G B235.1

G H C H A

H 2022, C C

G H 2022, H C H 2021,

I J 2024, G C D

H 2024 《深化醫藥衛生體制改革2024年重點工作任務》,

(固本革新,篤信行遠), H G

Management Discussion and Analysis

For the six months ended June 30,

G 收 入 总 额 为 RMB29.0 百 万 元 ， 较 上 年 同 期 增 长 6.6% 。 其 中 ， 医 疗 收 入 为 RMB27.5 百 万 元 ， 较 上 年 同 期 增 长 5.1% ； 医 药 收 入 为 RMB1.5 百 万 元 ， 较 上 年 同 期 增 长 27.5% （ 2023 年 同 期 为 RMB1.1 百 万 元 ） 。 其 中 ， 医 药 收 入 中 的 医 药 费 收 入 为 RMB1.1 百 万 元 ， 较 上 年 同 期 增 长 12.2% （ 2023 年 同 期 为 RMB0.9 百 万 元 ） 。 其 中 ， 医 药 费 收 入 中 的 医 药 费 收 入 为 RMB1.1 百 万 元 ， 较 上 年 同 期 增 长 15.9% （ 2023 年 同 期 为 RMB0.9 百 万 元 ） 。 其 中 ， 医 药 费 收 入 中 的 医 药 费 收 入 为 RMB1.1 百 万 元 ， 较 上 年 同 期 增 长 2.6% （ 2023 年 同 期 为 RMB1.1 百 万 元 ） 。

Revenue and Cost of Revenue

G 收 入 总 额 为 RMB29.0 百 万 元 ， 较 上 年 同 期 增 长 6.6% 。 其 中 ， 医 疗 收 入 为 RMB27.5 百 万 元 ， 较 上 年 同 期 增 长 5.1% ； 医 药 收 入 为 RMB1.5 百 万 元 ， 较 上 年 同 期 增 长 27.5% （ 2023 年 同 期 为 RMB1.1 百 万 元 ） 。 其 中 ， 医 药 收 入 中 的 医 药 费 收 入 为 RMB1.1 百 万 元 ， 较 上 年 同 期 增 长 12.2% （ 2023 年 同 期 为 RMB0.9 百 万 元 ） 。 其 中 ， 医 药 费 收 入 中 的 医 药 费 收 入 为 RMB1.1 百 万 元 ， 较 上 年 同 期 增 长 15.9% （ 2023 年 同 期 为 RMB0.9 百 万 元 ） 。 其 中 ， 医 药 费 收 入 中 的 医 药 费 收 入 为 RMB1.1 百 万 元 ， 较 上 年 同 期 增 长 2.6% （ 2023 年 同 期 为 RMB1.1 百 万 元 ） 。

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(RMB'000)
	(Unaudited)	(审 计 后)
医 疗 收 入	765,636	728,692
医 药 收 入	63,023	46,375
医 药 费 收 入	298	2,858
Total revenue	828,957	777,925

Management Discussion and Analysis

Revenue and cost of revenue from operating its owned hospitals

Revenue from operating its owned hospitals consists of fees (“Billing Revenue”)

	For the six months ended June 30, 2024 (RMB'000) (Unaudited)	2023 (RMB'000) (Unaudited)
Billing Revenue from owned hospitals	784,892	744,197
Less: Variable considerations	19,256	15,505
Revenue from operating owned hospitals – net	765,636	728,692

For the Reporting Period, the Group's Billing Revenue from its owned hospitals amounted to RMB784.9 million, representing an increase of 5.5% as compared with that of the same period of 2023, which was mainly due to an increase in treatment and general healthcare services revenue driven by higher outpatient visits and inpatient visits. During the Reporting Period, the variable considerations amounted to RMB19.3 million, representing an increase of RMB3.8 million as compared with that of the same period of 2023, the proportion of the variable considerations to Billing Revenue increased to 2.5% (for the six months ended June 30, 2023: 2.1%).

Management Discussion and Analysis

For the six months ended June 30, 2024, the Company's operating income was RMB 100,000,000, net profit was RMB 10,000,000, and the weighted average number of shares outstanding was 100,000,000 shares.

For the six months ended June 30,
2024
(RMB'000)
(Unaudited)

2023
(R'000)
(100,000)

Management Discussion and Analysis

	For the six months ended June 30,	
	2024	2023
	(Unaudited)	(Audited)
Inpatients		
I	11,648	10,573
E	2,119,936	1,914,613
(%)	87.4	84.0
	1,852,397	1,607,422
(\$'000)	586,146	553,572



Management Discussion and Analysis

Gross Profit and Gross Profit Margin

Item	2024	2023
Gross Profit	¥226.2 million	¥210.4 million
Gross Profit Margin	12.2%	16.1%

For the six months ended June 30,
2024 2023
(Unaudited)

Management Discussion and Analysis

Administrative Expenses

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	(Audited)
E	64,383	55,922
D	13,955	13,474
C	4,042	14,377
	2,199	2,071
	21,692	16,080
Total administrative expenses	106,271	101,924

Administrative expenses for the six months ended June 30, 2024, were RMB106.3 million, an increase of 4.3% compared with RMB101.9 million for the six months ended June 30, 2023. The increase was mainly due to the increase in employee benefits expense, which increased by 15.1% from RMB13.5 million in 2023 to RMB15.5 million in 2024. Other administrative expenses increased by 71.9% from RMB2.1 million in 2023 to RMB3.6 million in 2024. Depreciation and amortization expenses increased by 13.9% from RMB16.1 million in 2023 to RMB18.3 million in 2024. Other administrative expenses decreased by 71.9% from RMB14.4 million in 2023 to RMB4.0 million in 2024.

Management Discussion and Analysis

Finance Expenses – Net

For the six months ended June 30,		
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	()
I	-2,686	-2,705
F	99	-13
B	18,078	14,124
I	5,245	5,053
	2,968	3,151
	761	545
Finance expenses – net	24,465	20,160

Due to the impact of the exchange rate, the net finance expenses for the six months ended June 30, 2024, increased by RMB24,465 thousand compared with the net finance expenses of B20,160 thousand for the six months ended June 30, 2023.

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

Management Discussion and Analysis

Receipts in Advance and Contract Liabilities

At June 30, 2024, the amount of Receipts in Advance and Contract Liabilities was RMB26.3 million (2023: RMB26.6 million).

Other Payables

At June 30, 2024, the amount of Other Payables was RMB63.5 million (2023: RMB150.3 million), of which the amount of payables to related parties was RMB1.5 million. The amount of payables to related parties was RMB1.5 million, which was mainly due to the fact that the related parties had not yet paid the amount of the loan. The amount of payables to related parties was RMB1.5 million, which was mainly due to the fact that the related parties had not yet paid the amount of the loan.

	For the six months ended June 30, 2024 (RMB'000) (Unaudited)	2023 (RMB'000) (Audited)
Net Cash Generated from Operating Activities	116,536	113,591
Net Cash Used in Investing Activities	-112,711	-119,122
Net Cash Generated from Financing Activities	-41,660	9,790
Net Change in Cash and Cash Equivalents	-37,934	4,273

Net Cash Generated from Operating Activities

Net Cash Generated from Operating Activities was RMB116.5 million for the six months ended June 30, 2024 (2023: RMB113.6 million). The increase was mainly due to the fact that the company had a higher net income for the six months ended June 30, 2024 compared to the six months ended June 30, 2023.

Net Cash Used in Investing Activities

Net Cash Used in Investing Activities was RMB112.7 million for the six months ended June 30, 2024 (2023: RMB119.1 million). The decrease was mainly due to the fact that the company had a lower net cash outflow for the six months ended June 30, 2024 compared to the six months ended June 30, 2023.



Management Discussion and Analysis

Net Cash Generated from Financing Activities

2024 年 1-9 月，公司经营活动产生的现金流量净额为人民币 41.7 万元。

Significant Investment, Acquisition and Disposal

截至 2024 年 9 月 30 日，公司无重大投资、收购和处置。

截至 2024 年 9 月 30 日，公司无重大投资、收购和处置。

Bank Borrowings

截至 2024 年 9 月 30 日，公司无重大银行借款。截至 2023 年 12 月 31 日，公司无重大银行借款。

Contingent Liability

截至 2024 年 9 月 30 日，公司无重大或有负债。截至 2023 年 12 月 31 日，公司无重大或有负债。

Asset Pledge

截至 2024 年 9 月 30 日，公司无重大资产抵押。截至 2023 年 12 月 31 日，公司无重大资产抵押。

Management Discussion and Analysis

Lease Liabilities

At December 31, 2024, the Group's lease liabilities were RMB153.9 million, compared with RMB22.5 million at December 31, 2023. The increase is primarily due to the recognition of lease liabilities for the Group's new leases.

Financial Instruments

The Group's financial instruments include cash and cash equivalents, accounts receivable, accounts payable, other receivables, other payables, and bank borrowings. The Group's financial instruments are classified as financial assets or financial liabilities.

Exposure to Fluctuation in Exchange Rates

The Group's operations are primarily conducted in the PRC, and its assets and liabilities are denominated in RMB. The Group is exposed to exchange rate fluctuations primarily through its bank borrowings denominated in foreign currencies. The Group has adopted a risk management policy to manage the exchange rate risk. The Group's bank borrowings are primarily denominated in USD and HKD. The Group's bank borrowings are classified as financial liabilities.

Gearing Ratio

At December 31, 2024, the Group's gearing ratio (defined as total bank borrowings divided by total equity) was 52.6% (December 31, 2023: 53.3%).

Employees and Remuneration Policy

At December 31, 2024, the Group had 4,742 employees (December 31, 2023: 4,765). The Group's remuneration policy is to attract and retain qualified personnel. The Group's remuneration is primarily determined by the employee's position, experience, and performance. The Group's remuneration is classified as employee benefits.

The Group's remuneration policy is to attract and retain qualified personnel. The Group's remuneration is primarily determined by the employee's position, experience, and performance. The Group's remuneration is classified as employee benefits.

[illegible]

[illegible]

()

D

C

[illegible][illegible]

() E I

I 48 (J 28, 2022)

(J 29, 2015); I

E I

Management Discussion and Analysis

For the period from January 1, 2021, to December 31, 2022, the Company has not issued any incentive shares to its employees. The Company's incentive share plan is as follows:

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/Share)	Balance of	Balance of					Balance of
				Incentive Shares	Incentive Shares					Incentive Shares
				Granted but not Vested as at January 1, 2024	Granted and Vested as at January 1, 2024	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Granted but not Vested as at June 30, 2024
1. Mr. A G (曾 國 榮)	June 18, 2021	June 28, 2022	10.47	0	243,328	0	0	0	0	0
2. Mr. IE (梁 國 榮)	June 18, 2021	June 28, 2022	10.47	0	4,776	0	0	0	0	0
3. Mr. A G H (曾 國 榮)	June 18, 2021	June 28, 2022	10.47	0	23,653	0	0	0	0	0

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Vesting Date	Grant Price (RMB/ Share)	Balance of Incentive Shares	Balance of Incentive Shares	Granted during the Reporting Period	Vested	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares
				Granted but not Vested as at January 1, 2024	Granted and Vested as at January 1, 2024		(Unlocked) during the Reporting Period			Granted but not Vested as at June 30, 2024

7 4 ()



Management Discussion and Analysis

本公司在 2023 年度实现营业收入 36,100 万元，较 2022 年度增加 364,100 万元，增幅为 1.01%。其中，主营业务收入 35,000 万元，较 2022 年度增加 335,000 万元，增幅为 1.01%。其他业务收入 1,100 万元，较 2022 年度增加 100 万元，增幅为 1.66%。

2023 年度，公司实现营业收入 36,100 万元，较 2022 年度增加 364,100 万元，增幅为 1.01%。其中，主营业务收入 35,000 万元，较 2022 年度增加 335,000 万元，增幅为 1.01%。其他业务收入 1,100 万元，较 2022 年度增加 100 万元，增幅为 1.66%。

2023 年度，公司实现营业收入 36,100 万元，较 2022 年度增加 364,100 万元，增幅为 1.01%。其中，主营业务收入 35,000 万元，较 2022 年度增加 335,000 万元，增幅为 1.01%。其他业务收入 1,100 万元，较 2022 年度增加 100 万元，增幅为 1.66%。

2023 年度，公司实现营业收入 36,100 万元，较 2022 年度增加 364,100 万元，增幅为 1.01%。其中，主营业务收入 35,000 万元，较 2022 年度增加 335,000 万元，增幅为 1.01%。其他业务收入 1,100 万元，较 2022 年度增加 100 万元，增幅为 1.66%。

2023 年度，公司实现营业收入 36,100 万元，较 2022 年度增加 364,100 万元，增幅为 1.01%。其中，主营业务收入 35,000 万元，较 2022 年度增加 335,000 万元，增幅为 1.01%。其他业务收入 1,100 万元，较 2022 年度增加 100 万元，增幅为 1.66%。

2023 年度，公司实现营业收入 36,100 万元，较 2022 年度增加 364,100 万元，增幅为 1.01%。其中，主营业务收入 35,000 万元，较 2022 年度增加 335,000 万元，增幅为 1.01%。其他业务收入 1,100 万元，较 2022 年度增加 100 万元，增幅为 1.66%。

Corporate Governance and Other Information

C A E G E A CE

CGC

C IA CE I H HE DE C DE

C



Corporate Governance and Other Information

A DI C I EE A D E IE F HE I E I E, A D HE I E I E

C 3.21 3.22 H CG C B . A J 30, 2024, A C JI G 30, 2024

I E I DI IDE D

B 2024 B1.50 (10 HE I H E DED J E 30, 2024 C 74,600,300 . E 751,900 H B11,077,260 (), 21.31% D B H H B C EG C 2024 EG C 13, 2024.

Corporate Governance and Other Information

I. E. I. C (中華人民共和國企業所得稅法)
 J. 1, 2008, C
 10%
 H
 H CC
 A H
 H
 C
 H
 D

I. H H
 10%
 C
 H
 C
 10%
 10%
 10%
 C
 H
 C



Corporate Governance and Other Information

CHA GE I DI EC , E I A D E I A AGE E

• • • • • D • C •

E E AF E HE E I G E I D

• • • • • G • • • • •

CHA GE I DI EC , E I ' A D CHIEF E EC I E'

Corporate Governance and Other Information

DI C E F I E E

Directors', Supervisors' and Chief Executive's Interests in Securities

As of June 30, 2024, the interests of Directors, Supervisors and the Chief Executive in the Company's securities are as follows:

(1) Interests of Directors and Supervisors

(2) Interests of the Chief Executive

(3) Interests of the Company's Employees

Name of Directors	Class of Shares	Nature of Interest	Number of Shares	Total Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares ⁽¹⁾
Mr. Gao (2)	D	B	13,350,250 () 3,694,500 ()	22,044,750 ()	39.99%	29.55%
Mr. A G (2)	D	B	3,694,500 () 13,350,250 ()	22,044,750 ()	39.99%	29.55%
	H	B	149,300 ()	149,300 ()	0.77%	0.20%
Mr. A G J	D	B	100,000 ()	100,000 ()	0.13%	0.13%
	H	B	159,100 ()	159,100 ()	0.82%	0.21%
Mr. J (3)	D	I	4,540,000 ()	4,540,000 ()	8.22%	6.09%

(1) : ...

(2) : ...

(3) : ...

Corporate Governance and Other Information

As of December 31, 2024, the Company has a total of 7,466,666 shares outstanding, all of which are ordinary shares. The Company has no preferred shares. The Company's shares are listed on the Shanghai Stock Exchange and are traded under the ticker symbol 603013. The Company's shares are held by approximately 10,000 shareholders. The Company's shares are subject to the same rights and obligations as the shares of the Company's parent company, Wenzhou Kangning Hospital Co., Ltd. The Company's shares are not subject to any restrictions or limitations. The Company's shares are not subject to any voting rights or other special rights. The Company's shares are not subject to any dividends or other distributions. The Company's shares are not subject to any other special arrangements. The Company's shares are not subject to any other special arrangements.

Interests of Substantial Shareholders

As of December 31, 2024, the Company has identified the following substantial shareholders: (1) The Company's largest shareholder is the Central Enterprise Rural Industry Investment Fund Co., Ltd. (中央企業鄉村產業投資基金股份有限公司), which holds 7,466,666 shares, representing 13.51% of the Company's total issued shares. (2) The Company's second largest shareholder is the Shanghai Jinzhen Enterprise Management Center (Limited Partnership) (上海金浙企業管理中心(有限合夥)), which holds 4,540,000 shares, representing 6.09% of the Company's total issued shares. (3) The Company's third largest shareholder is the FA (2), which holds 4,540,000 shares, representing 6.09% of the Company's total issued shares. (4) The Company's fourth largest shareholder is the J (2), which holds 4,540,000 shares, representing 6.09% of the Company's total issued shares.

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate	
				Percentage in Same Class ⁽¹⁾	Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
C E 1. 融 C (中央企業鄉村產業投資基金股份有限公司)	D	B	7,466,666()	13.51%	10.00%
2. E 3. C () (上海金浙企業管理中心(有限合夥)) ⁽²⁾	D	I	4,540,000()	8.22%	6.09%
FA ⁽²⁾	D	I	4,540,000()	8.22%	6.09%
J ⁽²⁾	D	I	4,540,000()	8.22%	6.09%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
上海金浦健服股權投資管理有限公司 ⁽²⁾	D	I	4,540,000()	3.22%	6.09%
溫州金寧股權投資合夥企業(有限合夥)	D	B	4,540,000()	3.22%	6.09%
⁽⁶⁾	D	I	3,934,350()	7.21%	5.34%
上海檀英投資合夥企業(有限合夥)	D	B	4,519,003()	3.13%	6.06%
上海樂進投資合夥企業(有限合夥) ⁽³⁾	D	I	4,519,003()	3.13%	6.06%
上海正心谷投資管理有限公司	D	I	6,506,309()	11.77%	3.72%
上海盛歌投資管理有限公司 ⁽⁴⁾	D	I	6,506,309()	11.77%	3.72%
萬得信息技術股份有限公司	D	I	3,333,000()	6.03%	4.47%
上海荷花緣企業管理中心(有限合夥)	D	I	3,333,000()	6.03%	4.47%

Corporate Governance and Other Information

:

- (): 77
- (1) 74,600,300 55,260,000 D 19,340,300 H ()
- (2) FA 50% J E C () (上海金浙企業管理中心(有限合夥))

ASSETS	I	Balance as at the end of the period	B
Current assets:			
C	()	373,302,433.47	418,561,721.39
/			
F	()	7,599,178.13	7,350,293.53
D	()	763,849.74	
A	()	448,102,421.02	420,441,069.56
A	()	2,366,951.74	9,330,552.93
/			
/			
/	()	69,943,027.66	69,705,723.93
F	()	51,889,640.76	60,600,130.25
I			
I			
C			
A			
- /	()	3,053,787.78	353,020.39
/			
Total current assets		957,021,290.30	937,647,572.03

Consolidated Balance Sheets

截至 2024 年 12 月 31 日 (A 资产负债表) (B 资产负债表)

	Balance as at the end of the period	B
ASSETS	I	II
Non-current assets:		
Long-term equity investments	()	14,000,000.00
Long-term receivables	()	141,550,815.01
Long-term debt	()	64,751,652.55
Long-term prepayments	()	782,127,103.00
Long-term prepayments	()	234,034,296.61
Long-term prepayments	()	170,465,125.54
Long-term prepayments	()	307,875,476.38
Long-term prepayments	()	119,909,089.24
Long-term prepayments	()	156,750,581.45
Long-term prepayments	()	44,940,518.91
Long-term prepayments	()	14,925,823.45
Total non-current assets	2,051,330,482.14	2,060,039,034.76
Total assets	3,008,351,772.44	3,047,636,606.84

GUAN Weili JIN Hui WANG Minhui

LIABILITIES AND SHAREHOLDERS' EQUITY

Consolidated Balance Sheets

截至 2024 年 3 月 31 日止期间及期末资产负债表

(A 列 人民币千元 B 列 人民币元)

		Balance as at the end of the period	B 列
LIABILITIES AND SHAREHOLDERS' EQUITY	I		人民币元

Parent Company Balance Sheets

30, 2024

(A B)

	Balance as at the end of the period	B
ASSETS		
Current assets:		
C	167,239,404.12	136,337,559.21
F		
D		
A	() 55,989,746.68	43,066,557.69
A	6,900.00	223,131.12
I	() 622,922,583.60	600,443,325.53
I	9,687,901.11	11,131,002.59
I		
C		
A		
-		
	355,000.00	330,000.00
Total current assets	856,201,535.51	347,091,576.19

Parent Company Balance Sheets

30, 2024

(A B)

	Balance as at the end of the period	B
ASSETS	I	II
Non-current assets:		
D		
•		
A -		
A -	(77) 793,380,629.16	75,953,439.17
I		
- -	64,751,652.55	65,099,055.34
I		
F	283,949,624.57	25,701,322.35
C	394,874.50	113,600.00
•		
•		
•		
A -		
I	23,105,075.42	23,650,002.23
I		
I		
D		
I		
G		
•	16,120,799.75	15,459,271.72
D	16,099,597.14	14,605,690.36
- -	14,472,217.77	6,320,355.26
Total non-current assets	1,212,274,470.86	1,202,965,769.43
Total assets	2,068,476,006.37	2,050,057,345.62

GUAN Weili JIN Hui WANG Minhui

Parent Company Balance Sheets

30, 2024

(A B)

	Balance as at the end of the period	B
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
-	111,000,000.00	125,000,000.00
F		
D		
A	37,382,041.07	33,774,329.53
	3,483,707.09	4,172,410.35
C		
E	16,652,661.89	20,572,854.31
	2,812,623.38	1,603,746.33
	42,052,422.61	38,919,608.73
	59,854,608.34	173,615,500.00
Total current liabilities	273,238,064.38	397,658,449.25
Non-current liabilities:		
-	506,300,000.00	362,042,127.25
B		
I		
	16,710,574.36	25,855,234.63
D	8,582,203.00	8,734,099.00
D		
Total non-current liabilities	531,592,777.36	396,631,460.88
Total liabilities	804,830,841.74	794,289,910.13

Consolidated Income Statement

F 2024 30, 2024

(A ☒ 2 B ☒ ☒ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 11 ☐ 12 ☐ 13 ☐ 14 ☐ 15 ☐ 16 ☐ 17 ☐ 18 ☐ 19 ☐ 20 ☐ 21 ☐ 22 ☐ 23 ☐ 24 ☐ 25 ☐ 26 ☐ 27 ☐ 28 ☐ 29 ☐ 30 ☐ 31 ☐ 32 ☐ 33 ☐ 34 ☐ 35 ☐ 36 ☐ 37 ☐ 38 ☐ 39 ☐ 40 ☐ 41 ☐ 42 ☐ 43 ☐ 44 ☐ 45 ☐ 46 ☐ 47 ☐ 48 ☐ 49 ☐ 50 ☐ 51 ☐ 52 ☐ 53 ☐ 54 ☐ 55 ☐ 56 ☐ 57 ☐ 58 ☐ 59 ☐ 60 ☐ 61 ☐ 62 ☐ 63 ☐ 64 ☐ 65 ☐ 66 ☐ 67 ☐ 68 ☐ 69 ☐ 70 ☐ 71 ☐ 72 ☐ 73 ☐ 74 ☐ 75 ☐ 76 ☐ 77 ☐ 78 ☐ 79 ☐ 80 ☐ 81 ☐ 82 ☐ 83 ☐ 84 ☐ 85 ☐ 86 ☐ 87 ☐ 88 ☐ 89 ☐ 90 ☐ 91 ☐ 92 ☐ 93 ☐ 94 ☐ 95 ☐ 96 ☐ 97 ☐ 98 ☐ 99 ☐ 100 ☐ 101 ☐ 102 ☐ 103 ☐ 104 ☐ 105 ☐ 106 ☐ 107 ☐ 108 ☐ 109 ☐ 110 ☐ 111 ☐ 112 ☐ 113 ☐ 114 ☐ 115 ☐ 116 ☐ 117 ☐ 118 ☐ 119 ☐ 120 ☐ 121 ☐ 122 ☐ 123 ☐ 124 ☐ 125 ☐ 126 ☐ 127 ☐ 128 ☐ 129 ☐ 130 ☐ 131 ☐ 132 ☐ 133 ☐ 134 ☐ 135 ☐ 136 ☐ 137 ☐ 138 ☐ 139 ☐ 140 ☐ 141 ☐ 142 ☐ 143 ☐ 144 ☐ 145 ☐ 146 ☐ 147 ☐ 148 ☐ 149 ☐ 150 ☐ 151 ☐ 152 ☐ 153 ☐ 154 ☐ 155 ☐ 156 ☐ 157 ☐ 158 ☐ 159 ☐ 160 ☐ 161 ☐ 162 ☐ 163 ☐ 164 ☐ 165 ☐ 166 ☐ 167 ☐ 168 ☐ 169 ☐ 170 ☐ 171 ☐ 172 ☐ 173 ☐ 174 ☐ 175 ☐ 176 ☐ 177 ☐ 178 ☐ 179 ☐ 180 ☐ 181 ☐ 182 ☐ 183 ☐ 184 ☐ 185 ☐ 186 ☐ 187 ☐ 188 ☐ 189 ☐ 190 ☐ 191 ☐ 192 ☐ 193 ☐ 194 ☐ 195 ☐ 196 ☐ 197 ☐ 198 ☐ 199 ☐ 200 ☐ 201 ☐ 202 ☐ 203 ☐ 204 ☐ 205 ☐ 206 ☐ 207 ☐ 208 ☐ 209 ☐ 210 ☐ 211 ☐ 212 ☐ 213 ☐ 214 ☐ 215 ☐ 216 ☐ 217 ☐ 218 ☐ 219 ☐ 220 ☐ 221 ☐ 222 ☐ 223 ☐ 224 ☐ 225 ☐ 226 ☐ 227 ☐ 228 ☐ 229 ☐ 230 ☐ 231 ☐ 232 ☐ 233 ☐ 234 ☐ 235 ☐ 236 ☐ 237 ☐ 238 ☐ 239 ☐ 240 ☐ 241 ☐ 242 ☐ 243 ☐ 244 ☐ 245 ☐ 246 ☐ 247 ☐ 248 ☐ 249 ☐ 250 ☐ 251 ☐ 252 ☐ 253 ☐ 254 ☐ 255 ☐ 256 ☐ 257 ☐ 258 ☐ 259 ☐ 260 ☐ 261 ☐ 262 ☐ 263 ☐ 264 ☐ 265 ☐ 266 ☐ 267 ☐ 268 ☐ 269 ☐ 270 ☐ 271 ☐ 272 ☐ 273 ☐ 274 ☐ 275 ☐ 276 ☐ 277 ☐ 278 ☐ 279 ☐ 280 ☐ 281 ☐ 282 ☐ 283 ☐ 284 ☐ 285 ☐ 286 ☐ 287 ☐ 288 ☐ 289 ☐ 290 ☐ 291 ☐ 292 ☐ 293 ☐ 294 ☐ 295 ☐ 296 ☐ 297 ☐ 298 ☐ 299 ☐ 300 ☐ 301 ☐ 302 ☐ 303 ☐ 304 ☐ 305 ☐ 306 ☐ 307 ☐ 308 ☐ 309 ☐ 310 ☐ 311 ☐ 312 ☐ 313 ☐ 314 ☐ 315 ☐ 316 ☐ 317 ☐ 318 ☐ 319 ☐ 320 ☐ 321 ☐ 322 ☐ 323 ☐ 324 ☐ 325 ☐ 326 ☐ 327 ☐ 328 ☐ 329 ☐ 330 ☐ 331 ☐ 332 ☐ 333 ☐ 334 ☐ 335 ☐ 336 ☐ 337 ☐ 338 ☐ 339 ☐ 340 ☐ 341 ☐ 342 ☐ 343 ☐ 344 ☐ 345 ☐ 346 ☐ 347 ☐ 348 ☐ 349 ☐ 350 ☐ 351 ☐ 352 ☐ 353 ☐ 354 ☐ 355 ☐ 356 ☐ 357 ☐ 358 ☐ 359 ☐ 360 ☐ 361 ☐ 362 ☐ 363 ☐ 364 ☐ 365 ☐ 366 ☐ 367 ☐ 368 ☐ 369 ☐ 370 ☐ 371 ☐ 372 ☐ 373 ☐ 374 ☐ 375 ☐ 376 ☐ 377 ☐ 378 ☐ 379 ☐ 380 ☐ 381 ☐ 382 ☐ 383 ☐ 384 ☐ 385 ☐ 386 ☐ 387 ☐ 388 ☐ 389 ☐ 390 ☐ 391 ☐ 392 ☐ 393 ☐ 394 ☐ 395 ☐ 396 ☐ 397 ☐ 398 ☐ 399 ☐ 400 ☐ 401 ☐ 402 ☐ 403 ☐ 404 ☐ 405 ☐ 406 ☐ 407 ☐ 408 ☐ 409 ☐ 410 ☐ 411 ☐ 412 ☐ 413 ☐ 414 ☐ 415 ☐ 416 ☐ 417 ☐ 418 ☐ 419 ☐

[illegible]



Consolidated Income Statement

For the six months ended June 30, 2024

(All amounts in RMB Yuan unless otherwise stated)

Item	I	Amount for the current period	A 账 期 数
III. Operating profit (losses represented with "-" sign)		63,825,306.45	56,497,252.53
A 账 : 营业利润 ()	()	503,489.95	5,924,960.95
B 账 : 营业亏损 ()	()	2,816,219.76	2,215,131.37
IV. Total profit (total losses represented with "-" signs)		61,512,576.64	60,207,112.14
: I	()	16,516,143.35	11,477,550.07
V. Net profit (net losses represented with "-" signs)		44,996,433.29	48,729,232.07
() C 账 营业利润 ()			
1. 营业利润 ()			
2. 营业亏损 ()			
() C 账 营业利润 ()			
1. 营业利润 ()			
2. 营业亏损 ()			
VI. Other comprehensive income, net of tax			
() C 账 其他综合收益 ()			
1. C 账 其他综合收益 ()			
2. 其他综合收益 ()			
3. C 账 其他综合收益 ()			
4. C 账 其他综合收益 ()			

Consolidated Income Statement

F 30, 2024
(A B)

Item	Amount for the current period	A
()		
1.		
2. C		
3. A		
4. C		
5.		
6. E		
7.		
VII. Total comprehensive income	44,996,433.29	43,729,232.07
A	-1.57	50,723,744.20
A	-5,727,310.91	4,979,174.61
VIII. Earnings per share:		
() B (B)	() 0.68	0.59
() D (B)	() 0.68	0.59

-1.57

GUAN Weili JIN Hui WANG Minhui

Parent Company Income Statement

F 30, 2024
(A B)

Item	Amount for the current period	A
V. Other comprehensive income, net of tax		
()		
1. C		
2.		
3. C		
4. C		
()		
1.		
2. C		
3. A		
4. C		
5.		
6. E		
7.		
VI. Total comprehensive income	29,384,349.62	-8,676,844.29
VII. Earnings per share:		
() B (B)		
() D (B)		

GUAN Weili JIN Hui WANG Minhui

Parent Company Cash Flow Statement

F 30, 2024
(A B)

Item	Amount for the current period	A
I. Cash flows from operating activities:		
C 178,625,474.28	136,510,657.37	
C 334,259,258.00	491,763,053.70	
Sub-total of cash inflows of operating activities	512,884,732.28	628,273,716.07
C 66,197,024.94	30,195,550.90	
C 84,545,764.25	30,391,274.33	
2,949,959.92	433,377.67	
C 338,808,072.60	463,041,604.31	
Sub-total of cash outflows of operating activities	492,500,821.71	624,567,307.71
Net cash flows from operating activities	20,383,910.57	53,706,408.36
II. Cash flows from investing activities:		
C 16,657,744.50		
C 13,273,818.98		
10,427.00		
C 13,284,245.98	16,657,744.50	
Sub-total of cash inflows of investing activities	13,284,245.98	16,657,744.50
C 1,277,334.63	1,691,749.51	
C 7,200,000.00	29,166,900.00	
C 8,477,334.63	30,353,649.51	
Sub-total of cash outflows of investing activities	8,477,334.63	30,353,649.51
Net cash flows from investing activities	4,806,911.35	-14,200,905.01

Parent Company Cash Flow Statement

For the period from January 1, 2024 to December 31, 2024
(Amount in thousands of RMB)

Item	Amount for the current period	Amount for the prior period
III. Cash flows from financing activities:		
Cash received from issuing shares	293,000,000.00	199,050,000.00
Sub-total of cash inflows of financing activities	293,000,000.00	199,050,000.00
Cash paid for interest	276,792,127.25	101,150,000.00
Cash paid for dividends	35,406,263.84	12,364,450.26
Cash paid for other financing activities	25,472,250.00	79,243,750.00
Sub-total of cash outflows of financing activities	337,670,641.09	192,758,200.26
Net cash flows from financing activities	-44,670,641.09	6,291,799.74
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-119,720.72	13,070.04
V. Net increase in cash and cash equivalents	-19,599,539.89	45,810,373.13
Adjusted cash and cash equivalents at the beginning of the period	185,475,808.48	90,387,144.89
VI. Cash and cash equivalents at the end of the period	165,876,268.59	136,197,518.02

GUAN Weili

JIN Hui

WANG Minhui

Accounting Director

Accounting Officer

Accounting Officer

Consolidated Statement of Changes in Shareholders' Equity

F 30, 2024
(A B)

Items	Amount for the current period													
	Equity attributable to owners of the parent company													
	Other equity instruments					Other								
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserves	Surplus reserves	Provision for general risk	Retained earnings	Subtotal	Minority interests	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				862,686,600.69	12,587,011.74			38,399,577.13		311,956,229.16	1,265,064,686.24	143,141,250.58	1,408,205,946.82
II. Balance as at the beginning of the current year	74,600,300.00				862,686,600.69	12,587,011.74			38,399,577.13		311,956,229.16	1,265,064,686.24	143,141,250.58	1,408,205,946.82
III. Increases/decreases in the current period ("+" for increases)					-11,942,120.95	-9,440,179.03					28,343,654.20	25,841,712.28	-7,585,802.94	18,255,903.34
1. C					-8,566,709.51	-9,440,179.03					50,723,744.20	50,723,744.20	-5,727,300.91	44,996,433.29
2. C					-9,334,383.19	-9,440,179.03								
3. A														
4. D														
IV. Balance as at the end of the current year					767,673.68						-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00
1. C														
2. C														
3. A														
4. D														
V. Balance as at the end of the current year											-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00

王 明輝
WANG Minhui

Parent Company Statement of Changes in Shareholders' Equity

F 30, 2024
(A B)

Items	Amount for the current period									
	Other equity instruments									
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income			
							Special reserves	Surplus reserves	Retained earnings	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				871,230,628.64	12,587,011.74		38,399,577.13	284,123,941.46	1,255,767,435.49
A. C										
C										
II. Balance as at the beginning of the current year	74,600,300.00				871,230,628.64	12,587,011.74		38,399,577.13	284,123,941.46	1,255,767,435.49
III. Increases(decreases in the current period ("+" for increases)					-8,566,709.51	-9,440,179.03			7,004,259.62	7,877,729.14
1. C					-8,566,709.51	-9,440,179.03			29,384,349.62	29,384,349.62
2. C					-9,334,383.19	-9,440,179.03				873,469.52
3. A										105,795.84
4. C					767,673.68					767,673.68
III. Decreases in the current period ("-" for decreases)									-22,380,090.00	-22,380,090.00
1. C										
2. C										
3. C										
4. C										
5. C										
6. C										
IV. Balance as at the end of the period	74,600,300.00				862,663,919.13	3,146,832.71		38,399,577.13	291,128,201.08	1,263,645,164.63

GUAN Weili JIN Hui WANG Minhui

GUAN Weili

JIN HUI



H • WANG Minhui

Notes to the Financial Statements

F 30, 2024
(A B)

I. G

H C . . . (C) H (溫州市康寧精神康復醫院) F 1996. C H . D , C.

15, 2014, C . . . (溫州康寧醫院股份有限公司).

C E H 20, 2015. C .

A 30, 2024, C 0 9 .0030 ,600,300 0.5 () C

C C.

(I) Basis of preparation

Notes to the Financial Statements

F
(A B)

II. B (C)

(II) Going concern

(III) Statement of compliance with the Accounting Standards for Business Enterprises

F, A B E
C J 30, 2024 J 2024.

III.

(I) Major tax categories and tax rates

Tax categories	Tax basis	Tax rate
(A)	A	
	()	

Notes to the Financial Statements

F 30, 2024

(A B)

I .

: B D 31, 2023 (), 30, 2024 (), 30, 2023 ().

(I) Cash at bank and on hand

Items	Balance as at the end of the period	B
C	315,188.51	371,623.69
C	367,196,561.26	416,930,293.93
	5,790,683.70	1,509,793.72
	373,302,433.47	418,561,721.39

(II) Financial assets held for trading

Items	Balance as at the end of the period	B
F	7,599,178.13	7,350,293.53
I	7,599,178.13	7,350,293.53
	7,599,178.13	7,350,293.53

(III) Notes receivable

Items	Balance as at the end of the period	B
B	763,849.74	
	763,849.74	

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(IV) Accounts receivable

1. A

Aging	Balance as at the end of the period	B
1	443,637,522.96	425,333,221.01
1. 2	42,631,127.19	6,696,709.34
2. 3	4,507,504.01	4,430,032.30
3	10,140,966.30	7,730,009.57
-	500,917,120.46	444,739,973.22
	52,814,699.44	24,343,903.66
	448,102,421.02	420,441,069.56

2. A

Notes to the Financial Statements

F
(A B 30, 2024)

(C)

(IV) Accounts receivable (Continued)

2. A (C)

		Balance as at the end of the period	Provision for	
Item	Book balance	bad debts		

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(IV) Accounts receivable (Continued)

3. Changes in the current period						
Category	B Provided for	Recovered or reversed	Written-back or written-off	Other changes	Balance as at the end of the period	
12,554,552.28		-11,415,706.28			24,270,288.56	
11,494,321.35	17,050,089.50				28,544,410.88	
24,348,903.66	17,050,089.50	-11,415,706.28			52,814,699.44	

(V) Advances to suppliers

Balance as at the end of the period					B
Aging	Amount	Proportion (%)	A		(%)
1	2,326,232.07	98.28	9,048,941.18		92.05
1- 2			742,811.80		7.56
2- 3	7,919.67	0.33	6,000.00		0.06
3	32,800.00	1.39	32,800.00		0.33

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(VI) Other receivables

Items	Balance as at the end of the period	B
I	787,500.00	
	69,155,527.66	69,705,728.98
	69,943,027.66	69,705,728.98

1. /

Items	Balance as at the end of the period	B
	787,500.00	
	787,500.00	

2. (1) D

Aging	Balance as at the end of the period	B
1	50,656,821.58	53,412,990.26
1. 2	15,533,337.46	29,894,811.69
2. 3	33,706,673.72	8,912,677.15
3. 4	1,438,191.47	5,404,423.07
4. 5	1,977,221.69	742,744.83
5	4,436,981.60	3,835,239.68
-	107,749,227.52	102,252,886.68
	38,593,699.86	32,547,157.70
	69,155,527.66	69,705,728.98

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(VI) Other receivables (Continued)

2. (C)

(2) (C)

Balance as at the end of the period

Name	Book balance	Provision for bad debts	Proportion of provision (%)	B	B	
H H C . .	23,066,977.13	23,066,977.13	100.00		23,709,977.64	17,002,735.51
H H C . .	10,204,311.69	10,204,311.69	100.00		10,204,311.69	10,204,311.69
C (汪長勝)	3,490,447.08	3,490,447.08	100.00		3,490,447.08	3,490,447.08
	36,761,735.90	36,761,735.90			37,404,736.41	30,697,494.28

Balance as at the end of the period

Name	Other receivables	Provision for bad debts	Proportion of provision (%)
	70,987,491.62	1,831,963.96	2.58
	70,987,491.62	1,831,963.96	

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(VI) Other receivables (Continued)

2. (C)
(3) D

Provision for bad debts	Stage I	Stage II	Stage III	Total
	12-month ECL	Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
B				
1,349,663.42		30,697,494.23		32,547,157.70
B				
1,349,663.42				
-				
-				
-				
-				
6,064,241.62			6,064,241.62	6,064,241.62
17,423.93				17,423.93
270.43				270.43
B				
1,831,963.96		36,761,735.90		38,593,699.86

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(VI) Other receivables (Continued)

2. (C)

(3) D (C)

C :

Book balance	Stage I 12-month ECL	Stage II	Stage III	Total
		Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
B				
150.27	64,843		37,404,736.41	102,252,336.68
B				
/				
3 (4 0 () /C00) 9 1.0733 D1)				

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(VII) Inventories

Balance as at the end of the period		B		
Provision for decline in the value of inventories/impairment provision for contract performance				
Category	Book balance	costs	Book value	B
	1,230,185.02	1,230,185.02	1,616,773.62	1,616,773.62
G	541,753.33	541,753.33	4,571,610.32	4,571,610.32
C	50,117,702.41	50,117,702.41	54,411,790.31	54,411,790.31
	51,889,640.76	51,889,640.76	60,600,130.25	60,600,130.25

(VIII) Other current assets

Balance as at the end of the period		B		
Items				
		2,006,813.22		205,753.33
				4,363.35
		1,046,974.56		647,393.71
		3,053,787.78		353,020.39

(IX) Long-term receivables

Balance as at the end of the period		B		
Item	Book balance	Provision for bad debts	Book value	B
	14,000,000.00	14,000,000.00	14,000,000.00	14,000,000.00
	14,000,000.00	14,000,000.00	14,000,000.00	14,000,000.00

Notes to the Financial Statements

F 30, 2024
(A B)

Investees	Balance of the impairment provision as at the end of the previous year	Increase/decrease in the current period					Balance of the impairment provision as at the end of the period
		Investment profit/loss recognized under equity method	Other comprehensive income adjustment	Other equity changes	Cash dividends or profits declared and paid	Impairment provision	
A							
H A	16,018,884.93	687,659.39					16,706,544.37
H C	56,841,432.86	-166,415.53					56,675,017.33
H H	21,561,607.67	-393,224.24					21,168,383.43
H C H	22,287,534.75	712,327.54					22,999,862.29
C H H	18,649,398.65	-31,479.31					18,617,919.34
F H	3,713,128.14	-330,039.89					5,393,088.25
	139,071,987.05	478,827.96					141,550,815.01

X. Long-term equity investments

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XI) Other non-current financial assets

	Balance as at the end of the period	B
I		
F	64,751,652.55	65,099,055.34
I	64,751,652.55	65,099,055.34
	64,751,652.55	65,099,055.34

(XII) Fixed assets

1. F

Items	Balance as at the end of the period	B
F	782,127,103.00	794,356,342.94
D		
	782,127,103.00	794,356,342.94

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XIII) Construction in progress

1. C	Balance as at the end of the period					
	Book balance	Impairment provision	Carrying amount	B	I	C
Items						
C	234,034,296.61		234,034,296.61	136,930,240.67		136,930,240.67
C						
	234,034,296.61		234,034,296.61	136,930,240.67		136,930,240.67
2. D	Balance as at the end of the period					
	Book balance	Impairment provision	Carrying amount	B	I	C
Items						
H	137,317,869.97		137,317,869.97	101,029,929.74		101,029,929.74
C	89,526,711.76		89,526,711.76	35,174,600.41		35,174,600.41
H	3,766,450.99		3,766,450.99			
	3,423,263.89		3,423,263.89	775,710.52		775,710.52

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XIV) Right-of-use assets

Items	Buildings and structure	Total
1. (1) B	301,405,111.73	301,405,111.73
(2) I	70,403.22	70,403.22
(3) D	1,131,535.34	1,131,535.34
(4) B	300,343,934.11	300,343,934.11
2. (1) B	112,350,605.05	112,350,605.05
(2) I	13,029,069.41	13,029,069.41
(3) D	500,365.39	500,365.39
(4) B	129,878,808.57	129,878,808.57
3. (1) B		
(2) I		
(3) D		
(4) B		
4. (1) C	170,465,125.54	170,465,125.54
(2) C	139,054,506.63	139,054,506.63

Notes to the Financial Statements

F
(A B) 30, 2024

(C)

(XV) Intangible assets

	Land use rights	Trademark rights	Software	Medical practice qualifications	Contractual rights to provide management services	Total
1.						

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XVI) Goodwill

1. C

Name of the investees or events generating goodwill	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
		Arising from business combination	Disposal of goodwill impairment	
H 9,271,800.00	9,271,800.00			9,271,800.00
H 690,331.47	690,331.47			690,331.47
9,271,800.00 690,331.47 1,549,022.38	1,549,022.38			1,549,022.38
D 7,784,850.00	7,784,850.00			7,784,850.00
B 22,987,331.04	22,987,331.04			22,987,331.04
151,048.40	151,048.40			151,048.40
H 5,068,959.78	5,068,959.78			5,068,959.78
C 6,843,288.91	6,843,288.91			6,843,288.91
H 19,416,285.97	19,416,285.97			19,416,285.97
51,770,194.67	51,770,194.67			51,770,194.67
H 1,272,643.00	1,272,643.00			1,272,643.00
J 5,060,323.85	5,060,323.85			5,060,323.85
C 283,528.10	283,528.10			283,528.10
D 2,502,854.13	2,502,854.13			2,502,854.13
C 9,564,442.65	9,564,442.65			9,564,442.65
H 228,538.31	228,538.31			228,538.31
144,445,442.66	144,445,442.66			144,445,442.66

Notes to the Financial Statements

F 2024 30, 2024

(A ☒ 2 B ☒ ☒ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 11 ☐ 12 ☐ 13 ☐ 14 ☐ 15 ☐ 16 ☐ 17 ☐ 18 ☐ 19 ☐ 20 ☐ 21 ☐ 22 ☐ 23 ☐ 24 ☐ 25 ☐ 26 ☐ 27 ☐ 28 ☐ 29 ☐ 30 ☐ 31 ☐ 32 ☐ 33 ☐ 34 ☐ 35 ☐ 36 ☐ 37 ☐ 38 ☐ 39 ☐ 40 ☐ 41 ☐ 42 ☐ 43 ☐ 44 ☐ 45 ☐ 46 ☐ 47 ☐ 48 ☐ 49 ☐ 50 ☐ 51 ☐ 52 ☐ 53 ☐ 54 ☐ 55 ☐ 56 ☐ 57 ☐ 58 ☐ 59 ☐ 60 ☐ 61 ☐ 62 ☐ 63 ☐ 64 ☐ 65 ☐ 66 ☐ 67 ☐ 68 ☐ 69 ☐ 70 ☐ 71 ☐ 72 ☐ 73 ☐ 74 ☐ 75 ☐ 76 ☐ 77 ☐ 78 ☐ 79 ☐ 80 ☐ 81 ☐ 82 ☐ 83 ☐ 84 ☐ 85 ☐ 86 ☐ 87 ☐ 88 ☐ 89 ☐ 90 ☐ 91 ☐ 92 ☐ 93 ☐ 94 ☐ 95 ☐ 96 ☐ 97 ☐ 98 ☐ 99 ☐ 100 ☐ 101 ☐ 102 ☐ 103 ☐ 104 ☐ 105 ☐ 106 ☐ 107 ☐ 108 ☐ 109 ☐ 110 ☐ 111 ☐ 112 ☐ 113 ☐ 114 ☐ 115 ☐ 116 ☐ 117 ☐ 118 ☐ 119 ☐ 120 ☐ 121 ☐ 122 ☐ 123 ☐ 124 ☐ 125 ☐ 126 ☐ 127 ☐ 128 ☐ 129 ☐ 130 ☐ 131 ☐ 132 ☐ 133 ☐ 134 ☐ 135 ☐ 136 ☐ 137 ☐ 138 ☐ 139 ☐ 140 ☐ 141 ☐ 142 ☐ 143 ☐ 144 ☐ 145 ☐ 146 ☐ 147 ☐ 148 ☐ 149 ☐ 150 ☐ 151 ☐ 152 ☐ 153 ☐ 154 ☐ 155 ☐ 156 ☐ 157 ☐ 158 ☐ 159 ☐ 160 ☐ 161 ☐ 162 ☐ 163 ☐ 164 ☐ 165 ☐ 166 ☐ 167 ☐ 168 ☐ 169 ☐ 170 ☐ 171 ☐ 172 ☐ 173 ☐ 174 ☐ 175 ☐ 176 ☐ 177 ☐ 178 ☐ 179 ☐ 180 ☐ 181 ☐ 182 ☐ 183 ☐ 184 ☐ 185 ☐ 186 ☐ 187 ☐ 188 ☐ 189 ☐ 190 ☐ 191 ☐ 192 ☐ 193 ☐ 194 ☐ 195 ☐ 196 ☐ 197 ☐ 198 ☐ 199 ☐ 200 ☐ 201 ☐ 202 ☐ 203 ☐ 204 ☐ 205 ☐ 206 ☐ 207 ☐ 208 ☐ 209 ☐ 210 ☐ 211 ☐ 212 ☐ 213 ☐ 214 ☐ 215 ☐ 216 ☐ 217 ☐ 218 ☐ 219 ☐ 220 ☐ 221 ☐ 222 ☐ 223 ☐ 224 ☐ 225 ☐ 226 ☐ 227 ☐ 228 ☐ 229 ☐ 230 ☐ 231 ☐ 232 ☐ 233 ☐ 234 ☐ 235 ☐ 236 ☐ 237 ☐ 238 ☐ 239 ☐ 240 ☐ 241 ☐ 242 ☐ 243 ☐ 244 ☐ 245 ☐ 246 ☐ 247 ☐ 248 ☐ 249 ☐ 250 ☐ 251 ☐ 252 ☐ 253 ☐ 254 ☐ 255 ☐ 256 ☐ 257 ☐ 258 ☐ 259 ☐ 260 ☐ 261 ☐ 262 ☐ 263 ☐ 264 ☐ 265 ☐ 266 ☐ 267 ☐ 268 ☐ 269 ☐ 270 ☐ 271 ☐ 272 ☐ 273 ☐ 274 ☐ 275 ☐ 276 ☐ 277 ☐ 278 ☐ 279 ☐ 280 ☐ 281 ☐ 282 ☐ 283 ☐ 284 ☐ 285 ☐ 286 ☐ 287 ☐ 288 ☐ 289 ☐ 290 ☐ 291 ☐ 292 ☐ 293 ☐ 294 ☐ 295 ☐ 296 ☐ 297 ☐ 298 ☐ 299 ☐ 300 ☐ 301 ☐ 302 ☐ 303 ☐ 304 ☐ 305 ☐ 306 ☐ 307 ☐ 308 ☐ 309 ☐ 310 ☐ 311 ☐ 312 ☐ 313 ☐ 314 ☐ 315 ☐ 316 ☐ 317 ☐ 318 ☐ 319 ☐ 320 ☐ 321 ☐ 322 ☐ 323 ☐ 324 ☐ 325 ☐ 326 ☐ 327 ☐ 328 ☐ 329 ☐ 330 ☐ 331 ☐ 332 ☐ 333 ☐ 334 ☐ 335 ☐ 336 ☐ 337 ☐ 338 ☐ 339 ☐ 340 ☐ 341 ☐ 342 ☐ 343 ☐ 344 ☐ 345 ☐ 346 ☐ 347 ☐ 348 ☐ 349 ☐ 350 ☐ 351 ☐ 352 ☐ 353 ☐ 354 ☐ 355 ☐ 356 ☐ 357 ☐ 358 ☐ 359 ☐ 360 ☐ 361 ☐ 362 ☐ 363 ☐ 364 ☐ 365 ☐ 366 ☐ 367 ☐ 368 ☐ 369 ☐ 370 ☐ 371 ☐ 372 ☐ 373 ☐ 374 ☐ 375 ☐ 376 ☐ 377 ☐ 378 ☐ 379 ☐ 380 ☐ 381 ☐ 382 ☐ 383 ☐ 384 ☐ 385 ☐ 386 ☐ 387 ☐ 388 ☐ 389 ☐ 390 ☐ 391 ☐ 392 ☐ 393 ☐ 394 ☐ 395 ☐ 396 ☐ 397 ☐ 398 ☐ 399 ☐ 400 ☐ 401 ☐ 402 ☐ 403 ☐ 404 ☐ 405 ☐ 406 ☐ 407 ☐ 408 ☐ 409 ☐ 410 ☐ 411 ☐ 412 ☐ 413 ☐ 414 ☐ 415 ☐ 416 ☐ 417 ☐ 418 ☐ 419 ☐

I . • •)

(C)

(XVI) Goodwill (Continued)

2. $\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 1 \\ 1 & -1 \end{pmatrix} \frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 1 \\ 1 & -1 \end{pmatrix} = \frac{1}{2} \begin{pmatrix} 1 & 1 \\ 1 & -1 \end{pmatrix} \begin{pmatrix} 1 & 1 \\ 1 & -1 \end{pmatrix} = \frac{1}{2} \begin{pmatrix} 2 & 0 \\ 0 & 2 \end{pmatrix} = \begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix}$

∴ B'0,000

Name of goodwill asset groups or portfolio of asset groups	Composition and basis of asset groups or portfolio of asset groups	Carrying amount as at the end of the period	Consistent with the prior years or not
1. H. C. . . .	A. . . .	1,342.46	
H. . . .	A. . . .	1,645.65	
G. H. C. . . .	A. . . .	1,074.50	
. . . .	A. . . .	771.11	
B. H. C. . . .	A. . . .	4,178.64	
. H. . . .	A. . . .	14.48	
H. H. C. . . .	A. . . .	552.41	
C. H. C. . . .	A. . . .	1,278.50	
. C. H. C. . . .	A. . . .	3,726.83	
. C. . . . H. . . .	A. . . .	12,548.35	
H. . . .	A. . . .	181.32	
J. . . . H. C. . . .	A. . . .	7,011.47	
. C. . . . H. . . .	A. . . .	2,485.39	
D. . . . H. C. . . .	A. . . .	2,179.53	
C. . . . J. . . . H. C. . . .	A. . . .	2,792.84	
. A. . . . C. . . .	A. . . .	4.09	
		41,787.57	

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XVII) Long-term prepaid expenses

Items	B 1	Increase in the current period	Amortisation in the current period	Balance as at the end of the period
	175,706,029.27	1,863,337.07	21,012,423.47	156,556,942.87
	175,292.93	38,000.00	41,641.68	174,651.25
	26,303.94		7,316.61	18,987.33
	175,910,626.14	1,901,337.07	21,061,381.76	156,750,581.45

(XVIII) Deferred tax assets and deferred tax liabilities

Items	Balance as at the end of the period		B 1	
	Deductible temporary differences	Deferred tax assets	D 1 1	D
1 1 1	37,735,416.76	7,995,190.93	25,315,013.56	5,221,670.24
1 1 1	36,307,991.72	9,076,997.93	3,073,067.30	3,073,067.30
D 1	94,761,661.96	18,358,697.14	126,627,704.39	26,623,506.01
1 1 1	178,203,515.38	44,007,128.21	151,046,756.33	45,261,639.23
-	55,456,176.01	8,308,050.85	54,633,502.33	3,203,275.35
	402,464,761.83	87,746,065.06	390,754,045.46	33,333,203.63

Notes to the Financial Statements

F
(A
F
B
30, 2024
)

Notes to the Financial Statements

F 2024 30, 2024
(A B)

(C)

(XX) Assets with restricted ownership or right-of-use

	As at the end of the period				A					B	
			Types for	Case for							C
Items	Book balance	Carrying amount	restriction	restriction	B	C					
C				Bank acceptance deposit							B
	150,009.00	150,009.00	Guarantee	Performance bond	772,510.54	772,510.54	F				
	5,000,000.00	5,000,000.00	Guarantee	Foreign Exchange Control Account	12,000,000.00	12,000,000.00	F				
											F
	1,363,135.53	1,363,135.53	Freezing		2,120.75	2,120.75	F				E
					2,000.00	2,000.00	F				C
											A
	208,244,700.00	208,244,700.00	Pledge	Pledged loans	208,244,700.00	208,244,700.00					
				Sale and leaseback							
F	104,902,010.82	104,902,010.82	Mortgage	Secured borrowings	101,426,794.17	19,572,320.31					
	215,173,758.25	215,173,758.25	Mortgage	Secured borrowings	161,566,152.45	156,403,944.80					
I	26,041,873.00	26,041,873.00	Mortgage		59,523,533.00	52,511,079.33					
	240,799,717.53	240,799,717.53			231,904,499.27	274,392,040.60					

(XXI) Short-term borrowings

Items	Balance as at the end of the period	B
	111,000,000.00	125,000,000.00
		2,001,700.00
	111,000,000.00	127,001,700.00

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XXII) Financial liabilities held for trading

Items	Balance as at the end of the period	B
F 12,400,000.00	12,400,000.00	12,400,000.00

(XXIII) Accounts payable

Items	Balance as at the end of the period	B

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XXVI) Employee benefits payable (Continued)

3.

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
B	4,113,499.45	17,853,475.62	19,109,187.58	2,862,787.49
	141,199.04	593,688.95	648,098.81	86,789.18
	4,259,698.49	18,447,164.57	19,757,286.39	2,949,576.67

l

(XXVII) Taxes payable

Items	Balance as at the end of the period	B
(A)	2,694,016.67	3,056,261.74
E	22,926,288.67	30,600,774.99
I	1,720,787.95	1,143,039.23
C	104,506.51	134,739.29
	3,012,925.99	2,960,159.04
	74,789.97	96,590.13
	305,640.50	523,433.13
	13,843.13	31,053.22
E	2,094.00	1,369.00
	552.42	771.60
	30,855,445.81	33,553,746.47

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XXVIII) Other payables

Items	Balance as at the end of the period	B
I		35,313.43
D 2,370,000.00		624,000.00
	66,117,137.05	149,611,261.72
	68,487,137.05	150,270,575.15

1.

Items	Balance as at the end of the period	B
I		35,313.43
		35,313.43

2.

Items	Balance as at the end of the period	B
D 2,370,000.00		624,000.00
	2,370,000.00	624,000.00

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XXVIII) Other payables (Continued)

3.

Items	Balance as at the end of the period	B
	17,785,659.46	62,637,634.31
	1,313,457.77	1,313,457.77
	1,740,116.45	6,766,360.73
D	1,237,034.24	1,663,762.95
G	29,986,754.10	33,542,529.94
	3,677,029.66	9,345,641.23
A	8,254,225.35	23,431,495.22
	2,122,860.02	360,379.52
	66,117,137.05	149,611,261.72

(XXIX) Non-current liabilities due within one year

Items	Balance as at the end of the period	B
	44,136,233.34	130,020,000.00
	41,370,743.00	41,747,363.00
	22,779,404.91	23,643,333.99
	108,286,381.25	250,411,000.00

103.00

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XXX) Other current liabilities

Items	Balance as at the end of the period	B
A	5,575.47	
E	563,849.74	
	569,425.21	

(XXXI) Long-term borrowings

Items	Balance as at the end of the period	B
	89,166,233.34	212,342,127.25
G	306,620,000.00	252,010,000.00
	416,574,669.65	272,337,037.44
	44,136,233.34	130,020,000.00
	768,224,669.65	557,719,214.69

(XXXII) Lease liabilities

Items	Balance as at the end of the period	B
	158,912,952.10	163,239,532.76
	158,912,952.10	163,239,532.76

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XXXIII) Long-term accounts payable

Items	Balance as at the end of the period	B
	64,227,913.88	61,351,340.53
	64,227,913.88	61,351,340.53

I : -

Items	Balance as at the end of the period	B
F	105,598,656.88	103,099,205.53
I : 7	15,254,200.16	15,109,210.13
: -	41,370,743.00	41,747,365.00
	64,227,913.88	61,351,340.53

(XXXIV) Deferred income

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
G	8,734,099.00		151,896.00	8,582,203.00
	8,734,099.00		151,896.00	8,582,203.00

(XXXV) Share capital

Increase (+) decrease (-) in the current period							Balance as at the end of the period
Items	B	Issuance of new shares	Bonus issue	conversion from reserves	others	Subtotal	
	74,600,300.00						74,600,300.00

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XXXVI) Capital surplus

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
C	781,037,804.26		12,709,794.63	768,328,009.63
	44,857,374.20	767,673.68		45,625,047.88
	26,800,423.23			26,800,423.23
	852,695,601.69	767,673.68	12,709,794.63	840,753,480.74

(XXXVII) Treasury stock

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
C	12,587,011.74		9,440,179.03	3,146,832.71
	12,587,011.74		9,440,179.03	3,146,832.71

(XXXVIII) Surplus reserve

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
	38,399,577.13			38,399,577.13
	38,399,577.13			38,399,577.13

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XXXIX) Retained earnings

Items	Amount for the current period	A
	311,956,229.16	233,506,534.43
A		
(+ -)		
	311,956,229.16	233,506,534.43
A :		
	50,723,744.20	35,947,306.64
: A		
A		
A		
D	22,380,090.00	7,493,111.91
D		
	340,299,883.36	311,956,229.16

(XL) Revenue and cost of sales

1. A

Items	Amount for the current period		A	
	Revenue	Cost		C
	765,636,198.08	555,217,793.42	723,692,633.43	547,491,901.17
	63,321,355.63	47,582,667.69	49,232,530.41	23,393,694.59
	828,957,553.71	602,800,461.11	777,925,163.84	576,390,595.76

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XL) Revenue and cost of sales (Continued)

1. A (C)
B :

Items	Amount for the current period	A
	765,636,198.08	725,692,633.43
	765,636,198.08	725,692,633.43
	63,321,355.63	49,232,530.41
	41,715,643.36	25,551,507.57
	7,958,001.19	1,455,145.50
	297,619.53	2,557,971.77
	13,350,091.55	16,007,602.57
	828,957,553.71	777,925,163.54

2. D

Items	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
	A	B	D			

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XLI) Taxes and charges

Items	Amount for the current period	A
	4,886,926.23	1,704,919.27
C	460,954.07	393,619.06
B	331,720.92	234,361.36
	445,099.29	244,223.99
	130,348.60	139,457.31
	13,249.84	11,774.66
	6,268,298.95	2,733,361.65

(XLII) Selling and distribution expenses

Items	Amount for the current period	A
E	5,264,561.40	4,571,354.43
D	99,249.43	96,371.30
A	21,787.27	22,513.69
A	155,095.54	155,131.63
E	435,531.57	316,393.31
	316,961.17	130,167.93
	179,730.55	167,234.65
		10,473.13
	219,294.83	235,341.00
	2,388,776.86	2,020,072.51
	139,038.00	25,263.40
	29,239.82	27,732.42
	9,249,266.44	7,323,610.00

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XLIII) General and administrative expenses

Items	Amount for the current period	A
E	63,615,210.18	55,921,762.53
D	7,553,031.91	6,990,039.75
A	1,874,457.13	1,300,111.04
A	4,527,100.72	4,634,159.30
	963,471.75	1,039,347.77
H	1,323,759.68	1,336,037.33
E	767,673.68	
	2,276,602.65	1,700,201.12
	2,198,731.91	2,070,523.66
	351,396.86	717,753.37
	2,919,344.90	1,676,255.06
C	1,024,421.20	1,263,793.76
	1,308,692.84	1,532,961.73
C	1,815,859.33	14,377,209.14
A	2,226,500.13	
	5,421,178.66	3,243,243.19
E	2,803,324.36	2,599,553.04
	3,300,625.81	366,013.32
	106,271,383.70	101,924,026.76

(XLIV) Research and development expenses

Items	Amount for the current period	A
E	17,015,841.55	13,993,396.69
D	313,121.72	191,563.31
	23,806.46	92,076.43
	1,279.22	1,369.72
	7,292.41	333,933.66
	7,536.00	
	219,198.79	235,100.27
	17,588,076.15	14,957,995.63

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XLV) Financial expenses

Items	Amount for the current period	A
I	23,323,466.98	19,182,137.46
I 1	5,245,075.86	5,058,106.16
I 2	2,686,209.46	2,704,831.09
F	99,244.67	-13,070.04
	3,728,948.96	3,695,397.63
	24,465,451.15	20,159,633.96

(XLVI) Other income

Items	Amount for the current period	A
G	5,386,176.18	5,600,421.10
A	13,945.83	200,405.44
F	188,141.27	21,668.61
	5,588,263.28	5,822,495.15

(XLVII) Investment income

Items	Amount for the current period	A
I	478,827.96	-157,522.45
I 1	1,201,371.61	-38,203.48
	1,680,199.57	-195,725.93

Notes to the Financial Statements

F 2024 12 31 30, 2024
(A 12 12 B 12 12)

1. (C 12)

(XLVIII) Gain from change in fair value

Source of gains from changes in fair value	Amount for the current period	A 12 12
F 12 12 12 12	248,879.60	
- 12 12	-347,402.79	
	-98,523.19	

(XLIX) Credit impairment losses

Items	Amount for the current period	A 12 12
-------	-------------------------------	---------

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(LIII) Income tax expenses

1.

Items	Amount for the current period	A
	19,082,552.41	23,358,206.57
	-2,566,409.06	-11,880,326.50
	16,516,143.35	11,477,880.07

2.

Items	Amount for the current period
	61,512,576.64
	12,647,013.90
	474,180.04
	-769,492.74
	817,638.14
	-4,610,218.14
	9,615,739.59
	-3,065,849.16
	1,407,131.72
	16,516,143.35

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(LIV) Earnings per share

1. B

B
C

Items	Amount for the current period	A
C	50,723,744.20	43,750,057.46
C	74,600,300.00	74,600,300.00
B	0.68	0.59
I : B	0.68	0.59
B		

2. D

D
C

Items	Amount for the current period	A
C	50,723,744.20	43,750,057.46
C	74,600,300.00	74,600,300.00
D	0.68	0.59
I : D	0.68	0.59
D		

F • • J 30, 2024
(A t B t)

1.

(LV) Supplementary information to the cash flow statement (Continued)

1. $\frac{1}{2}$ $\frac{1}{2}$ $(C, \frac{1}{2}, \frac{1}{2})$

	Amount for the current period	A	B
2.			
C			
C			
-			
3.			
C	366,789,288.94	262,365,904.62	
: C	404,723,339.37	255,595,990.97	
A : C			
: C			
	-37,934,050.43	4,272,913.65	

2. C $\cap$ $\bullet$ $\boxtimes$

Items	Balance as at the end of the period	B
I. C	366,789,288.94	262,863,904.62
I. C	315,188.51	209,133.36
C		
C	365,833,425.73	262,235,513.11
C	640,674.70	424,203.15
II. C		
I. C		
B		
III. C	366,789,288.94	262,863,904.62
I. C		
C		
C		
G		

Notes to the Financial Statements

F 30, 2024
(A B)

Name of Subsidiary	Type of legal entity	Registered capital (RMB' 0,000)	Major business location	Place of registration	Nature of business	Shareholding (%)		Method of acquisition
						Direct	Indirect	
Wenzhou Kangning Hospital Co., Ltd.	C	2,040.92	H	H			99.00	I
Wenzhou Kangning Hospital Co., Ltd. D	C	50.00			D		100.00	I
Wenzhou Kangning Hospital Co., Ltd. I H ()	C	500.00			H		100.00	I
Wenzhou Kangning Hospital Co., Ltd. D	C	1,000.00					99.00	I
C Wenzhou Kangning Hospital Co., Ltd. H	C	2,200.00	C	C			64.55	C
H Wenzhou Kangning Hospital Co., Ltd. E & D	C	500.00	H	H			100.00	I
H Wenzhou Kangning Hospital Co., Ltd. C	C	100.00	H	H			100.00	I
Wenzhou Kangning Hospital Co., Ltd. H C	C	5,000.00					100.00	I
Wenzhou Kangning Hospital Co., Ltd. H	C	6,000.00					55.00	I
Wenzhou Kangning Hospital Co., Ltd. H C ()								

Notes to the Financial Statements

F 30, 2024
(A B)

1. (C)

(I) Interests in subsidiaries (Continued)

2. - - 9 7 7

Name of Subsidiary	Shareholding percentage of non-controlling shareholder	Current profits or losses attributable to non-controlling shareholders	Current dividends distributed to non-controlling shareholders	Closing balance of interest of non-controlling shareholders
H C . .	40.00%	44,636.00		30,411,626.36
J H H C . .	45.00%	-1,622,191.24		16,064,103.54

3. 9 7 7 - - 9 7 7

Name of Subsidiary	Balance as at the end of the period						B					
	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities	00	-00		00	-00	
H C . .	8,793,123.17	162,275,430.25	171,068,553.42	39,487.47	95,000,000.00	95,039,487.47	12,771,926.28	126,317,515.02	139,089,441.30	48,340.35	75,123,750.00	75,172,090.35
J H H C . .	8,951,720.53	70,164,028.21	79,115,748.74	14,151,720.45	28,010,857.21	42,162,577.66	13,868,975.32	71,012,513.90	84,881,489.22	15,643,448.52	28,680,000.20	44,323,448.72
Name of Subsidiary	Amount for the current period						A					
	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities								
H C . .		111,715.00	111,715.00	7,479,658.56					-1,000,974.74	-1,000,974.74	-3,869,458.16	
J H H C . .	9,111,507.81	-3,604,869.42	-3,604,869.42	-2,290,097.91			16,050,977.70		-2,862,161.57	-2,862,161.57	-8,603,908.46	

Notes to the Financial Statements

F 30, 2024
(A B)

I. (C)

(II) Transactions that cause changes in the share of owners' equity in subsidiaries that do not result in loss of control

1. E
I F 2024, B
H C , C
B A I B0.3 B1
B15,300,000.00.
B H C B46,536,700.00,
C 51% 67.77%.
A C
B3,375,411.44,

(III) Interests in joint arrangements or associates

1.

Name of joint venture or associate	Major business location	Place of registration	Nature of business	Shareholding (%)		Accounting method for investment in joint ventures or associates	Whether strategic to the Company's activities or not
				Direct	Indirect		
H C , .				45.00		E	
H C , .			H		30.00	E	

Notes to the Financial Statements

F 2024 30, 2024
(A B)

I. (C)

(III) Interests in joint arrangements or associates (Continued)

2.	Closing balance/amount for the current period		/	
	Wenzhou Longwan Yining Hospital Co., Ltd.	Shaanxi Shanda Hospital Management Consulting Co., Ltd.	H C	H C
	5,919,113.19	44,911,330.78	46,656,767.88	71,300,257.36
-	192,825,147.06	112,258,865.02	152,199,429.22	117,230,334.02
	198,744,260.25	157,170,195.80	198,856,197.10	188,530,591.38
	37,799,777.29	80,049,646.18	37,541,901.86	97,460,588.12
-	35,000,000.00	454,341.99	35,000,000.00	15,000,000.00
	72,799,777.29	80,503,988.17	72,541,901.86	112,460,588.12
-		17,565,753.51		19,343,974.26
E	125,944,482.96	59,100,454.12	126,314,295.24	56,726,029.00
	56,675,017.33	22,999,862.29	56,841,432.86	22,821,000.98
A				
- G				
C				
F				
		45,293,374.09		47,654,671.86
	-369,812.28	2,374,425.12	-257,993.98	1,052,984.93
	-369,812.28	2,374,425.12	-257,993.98	1,052,984.93
D				

Notes to the Financial Statements

F 30, 2024

(A B)

II. Various risks associated with financial instruments

(I) Various risks associated with financial instruments

Our financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. These instruments are subject to various risks, including credit risk, liquidity risk, and market risk. We have established policies and procedures to manage these risks and ensure the safety and soundness of our financial position.

Credit Risk: Credit risk is the risk of loss due to the failure of a counterparty to fulfill its contractual obligations. We manage credit risk by performing credit assessments on our counterparties and maintaining adequate reserves for potential losses.

Liquidity Risk: Liquidity risk is the risk of being unable to meet our financial obligations as they come due. We manage liquidity risk by maintaining a diverse portfolio of liquid assets and ensuring that we have sufficient cash and cash equivalents to meet our obligations.

Market Risk: Market risk is the risk of changes in the fair value of our financial instruments due to changes in market prices. We manage market risk by using derivative instruments to hedge our exposure to market price movements.

Our financial instruments are primarily denominated in U.S. dollars. We have established policies and procedures to manage the risks associated with foreign exchange rates, including the use of forward contracts and other derivative instruments.

1. Our financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. These instruments are subject to various risks, including credit risk, liquidity risk, and market risk. We have established policies and procedures to manage these risks and ensure the safety and soundness of our financial position.

Credit Risk: Credit risk is the risk of loss due to the failure of a counterparty to fulfill its contractual obligations. We manage credit risk by performing credit assessments on our counterparties and maintaining adequate reserves for potential losses.

Liquidity Risk: Liquidity risk is the risk of being unable to meet our financial obligations as they come due. We manage liquidity risk by maintaining a diverse portfolio of liquid assets and ensuring that we have sufficient cash and cash equivalents to meet our obligations.

Market Risk: Market risk is the risk of changes in the fair value of our financial instruments due to changes in market prices. We manage market risk by using derivative instruments to hedge our exposure to market price movements.

Our financial instruments are primarily denominated in U.S. dollars. We have established policies and procedures to manage the risks associated with foreign exchange rates, including the use of forward contracts and other derivative instruments.

Notes to the Financial Statements

F 30, 2024
(A B)

II. (C)

(I) Various risks associated with financial instruments (Continued)

2. (C)

C :
Closing balance

Items	Instant repayment	Within 1 year	1-2 years	2-5 years	Over 5 years	Total undiscounted contract amount	Book value
A		112,544,938.03				112,544,938.03	112,544,938.03
		68,487,137.05				68,487,137.05	68,487,137.05
-		111,000,000.00				111,000,000.00	111,000,000.00
-							
•		108,286,381.25				108,286,381.25	108,286,381.25
•			287,545,000.00	314,094,120.00	166,585,549.65	768,224,669.65	768,224,669.65
•			18,133,866.38	54,983,512.27	95,622,594.14	168,739,972.79	158,912,952.10
•			25,945,947.15	45,352,431.95		71,298,379.10	64,227,913.88
		400,318,456.33	331,624,813.53	414,430,064.22	262,208,143.79	1,408,581,477.87	1,210,651,916.88

B

10,143.7324 0 8,023 5 227.56 3

(I) Various risks associated with financial instruments *(Continued)*

[illegible]

(1) Γ is a $\mathbb{Z}$ -module

[illegible]

| - 𐤀 𐤁 𐤂 𐤃 𐤄 𐤅 𐤆 𐤇 𐤈 𐤉 𐤊 𐤋 𐤌 𐤍 𐤎 𐤏 𐤐 𐤑 𐤒 𐤓 𐤔 𐤕 𐤖 𐤗 𐤘 𐤙 𐤚 𐤛 𐤜 𐤝 𐤞 𐤟 𐤠 𐤡 𐤢 𐤣 𐤤 𐤥 𐤦 𐤧 𐤨 𐤩 𐤪 𐤫 𐤬 𐤭 𐤮 𐤯 𐤰 𐤱 𐤲 𐤳 𐤴 𐤵 𐤶 𐤷 𐤸 𐤹 𐤺 𐤻 𐤼 𐤽 𐤾 𐤿 𐥀 𐥁 𐥂 𐥃 𐥄 𐥅 𐥆 𐥇 𐥈 𐥉 𐥊 𐥋 𐥌 𐥍 𐥎 𐥏 𐥐 𐥑 𐥒 𐥓 𐥔 𐥕 𐥖 𐥗 𐥘 𐥙 𐥚 𐥛 𐥜 𐥝 𐥞 𐥟 𐥠 𐥡 𐥢 𐥣 𐥤 𐥥 𐥦 𐥧 𐥨 𐥩 𐥪 𐥫 𐥬 𐥭 𐥮 𐥯 𐥰 𐥱 𐥲 𐥳 𐥴 𐥵 𐥶 𐥷 𐥸 𐥹 𐥺 𐥻 𐥼 𐥽 𐥾 𐥿 𐦀 𐦁 𐦂 𐦃 𐦄 𐦅 𐦆 𐦇 𐦈 𐦉 𐦊 𐦋 𐦌 𐦍 𐦎 𐦏 𐦐 𐦑 𐦒 𐦓 𐦔 𐦕 𐦖 𐦗 𐦘 𐦙 𐦚 𐦛 𐦜 𐦝 𐦞 𐦟 𐦠 𐦡 𐦢 𐦣 𐦤 𐦥 𐦦 𐦧 𐦨 𐦩 𐦪 𐦫 𐦬 𐦭 𐦮 𐦯 𐦰 𐦱 𐦲 𐦳 𐦴 𐦵 𐦶 𐦷 𐦸 𐦹 𐦺 𐦻 𐦼 𐦽 𐦾 𐦿 𐧀 𐧁 𐧂 𐧃 𐧄 𐧅 𐧆 𐧇 𐧈 𐧉 𐧊 𐧋 𐧌 𐧍 𐧎 𐧏 𐧐 𐧑 𐧒 𐧓 𐧔 𐧕 𐧖 𐧗 𐧘 𐧙 𐧚 𐧛 𐧜 𐧝 𐧞 𐧟 𐧠 𐧡 𐧢 𐧣 𐧤 𐧥 𐧦 𐧧 𐧨 𐧩 𐧪 𐧫 𐧬 𐧭 𐧮 𐧯 𐧰 𐧱 𐧲 𐧳 𐧴 𐧵 𐧶 𐧷 𐧸 𐧹 𐧺 𐧻 𐧼 𐧽 𐧾 𐧿 𐨀 𐨁 𐨂 𐨃 𐨄 𐨅 𐨆 𐨇 𐨈 𐨉 𐨊 𐨋 𐨌 𐨍 𐨎 𐨏 𐨐 𐨑 𐨒 𐨓 𐨔 𐨕 𐨖 𐨗 𐨘 𐨙 𐨚 𐨛 𐨜 𐨝 𐨞 𐨟 𐨠 𐨡 𐨢 𐨣 𐨤 𐨥 𐨦 𐨧 𐨨 𐨩 𐨪 𐨫 𐨬 𐨭 𐨮 𐨯 𐨰 𐨱 𐨲 𐨳 𐨴 𐨵 𐨶 𐨷 𐨸 𐨹 𐨺 𐨻 𐨼 𐨽 𐨾 𐨿 𐩀 𐩁 𐩂 𐩃 𐩄 𐩅 𐩆 𐩇 𐩈 𐩉 𐩊 𐩋 𐩌 𐩍 𐩎 𐩏 𐩐 𐩑 𐩒 𐩓 𐩔 𐩕 𐩖 𐩗 𐩘 𐩙 𐩚 𐩛 𐩜 𐩝 𐩞 𐩟 𐩠 𐩡 𐩢 𐩣 𐩤 𐩥 𐩦 𐩧 𐩨 𐩩 𐩪 𐩫 𐩬 𐩭 𐩮 𐩯 𐩰 𐩱 𐩲 𐩳 𐩴 𐩵 𐩶 𐩷 𐩸 𐩹 𐩺 𐩻 𐩼 𐩽 𐩾 𐩿 𐪀 𐪁 𐪂 𐪃 𐪄 𐪅 𐪆 𐪇 𐪈 𐪉 𐪊 𐪋 𐪌 𐪍 𐪎 𐪏 𐪐 𐪑 𐪒 𐪓 𐪔 𐪕 𐪖 𐪗 𐪘 𐪙 𐪚 𐪛 𐪜 𐪝 𐪞 𐪟 𐪠 𐪡 𐪢 𐪣 𐪤 𐪥 𐪦 𐪧 𐪨 𐪩 𐪪 𐪫 𐪬 𐪭 𐪮 𐪯 𐪰 𐪱 𐪲 𐪳 𐪴 𐪵 𐪶 𐪷 𐪸 𐪹 𐪺 𐪻 𐪼 𐪽 𐪾 𐪿 𐫀 𐫁 𐫂 𐫃 𐫄 𐫅 𐫆 𐫇 𐫈 𐫉 𐫊 𐫋 𐫌 𐫍 𐫎 𐫏 𐫐 𐫑 𐫒 𐫓 𐫔 𐫕 𐫖 𐫗 𐫘 𐫙 𐫚 𐫛 𐫜 𐫝 𐫞 𐫟 𐫠 𐫡 𐫢 𐫣 𐫤 𐫥 𐫦 𐫧 𐫨 𐫩 𐫪 𐫫 𐫬 𐫭 𐫮 𐫯 𐫰 𐫱 𐫲 𐫳 𐫴 𐫵 𐫶 𐫷 𐫸 𐫹 𐫺 𐫻 𐫼 𐫽 𐫾 𐫿 𐬀 𐬁 𐬂 𐬃 𐬄 𐬅 𐬆 𐬇 𐬈 𐬉 𐬊 𐬋 𐬌 𐬍 𐬎 𐬏 𐬐 𐬑 𐬒 𐬓 𐬔 𐬕 𐬖 𐬗 𐬘 𐬙 𐬚 𐬛 𐬜 𐬝 𐬞 𐬟 𐬠 𐬡 𐬢 𐬣 𐬤 𐬥 𐬦 𐬧 𐬨 𐬩 𐬪 𐬫 𐬬 𐬭 𐬮 𐬯 𐬰 𐬱 𐬲 𐬳 𐬴 𐬵 𐬶 𐬷 𐬸 𐬹 𐬺 𐬻 𐬼 𐬽 𐬾 𐬿 𐭀 𐭁 𐭂 𐭃 𐭄 𐭅 𐭆 𐭇

Notes to the Financial Statements

F 30, 2024

$$(A \begin{array}{|c|} \hline \times \\ \hline \end{array} \cap B \begin{array}{|c|} \hline \times \\ \hline \end{array} \begin{array}{|c|} \hline \times \\ \hline \end{array} \cap \bullet)$$

II. $\gamma \bullet \gamma \gamma \boxtimes (C \gamma \boxtimes \bullet)$

(I) Various risks associated with financial instruments *(Continued)*

3. $\gamma(C \rightarrow \bullet)$

$$(2) \quad E \rightarrow \gamma$$
[illegible]

Figure 10: A diagram illustrating the construction of a new set of generators for the group G . The diagram shows a sequence of elements $a_1, a_2, \dots, a_n$ and $b_1, b_2, \dots, b_m$ arranged in a grid. The elements are connected by arrows indicating a sequence of operations. The diagram is labeled with C and G at various points, indicating the context of the construction.

Figure 1. The three types of the *Phragmites* communities in the coastal wetlands of the Yangtze River Delta. A: *Phragmites australis* community; B: *Phragmites australis* community with *Spartina patens*; C: *Phragmites australis* community with *Spartina patens* and *Spartina patens*.

Items	Closing balance			B		
	US\$	Other foreign currencies	Total	\$	€	¥
C	285,090.74	45,278.51	330,369.25	31,905.11	52,061.43	133,966.54
	285,090.74	45,278.51	330,369.25	31,905.11	52,061.43	133,966.54

C 30, 2024, 7, 31, 2023: B9,911.08 (D 31, 2023: B4,019.00) 3%.

Notes to the Financial Statements

F 30, 2024

(A B)

III. D (C)

(I) Closing fair value of assets and liabilities measured at fair value

Items	Closing fair value			Total
	Measured at fair value at Level 1	Measured at fair value at Level 2	Measured at fair value at Level 3	
I. Continuous measurement of fair value				
F _{7,599,173.13}			7,599,173.13	7,599,173.13
1. F _{7,599,173.13}			7,599,173.13	7,599,173.13
(1) I				
(2) I			7,599,173.13	7,599,173.13
2. F _{7,599,173.13}				
1. F _{64,751,652.55}			64,751,652.55	64,751,652.55
(1) I				
(2) I			64,751,652.55	64,751,652.55
Total assets with continuous measurement of fair value				72,350,330.68
F _{12,400,000.00}			12,400,000.00	12,400,000.00
1. F _{12,400,000.00}			12,400,000.00	12,400,000.00
(1) E				
(2) D				
(3)			12,400,000.00	12,400,000.00
2. F _{12,400,000.00}				
Total liabilities with continuous measurement of fair value				12,400,000.00

va

- 7

Notes to the Financial Statements

F
(A
J
B
30, 2024
)

I .
γ
γ
γ

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(IV) Information of other related parties

Name of other related parties	Other related parties' relationship with the Company			
C	-			C
C	-			C
J D	-			C
B A	-			C
(寧波梅山保稅港區寬展投資管理合夥企業(有限合夥))				
H C	-			C
H			C	
	C			
	-			C
	-			C
	-			C
H C	-			C
C	D			
H C	-			C
E C	-			C
C	-			C
H H C	I			C
A C				C
H C				C

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(V) Information on related party transactions

1. /

Related party	Amount for the period	A
F C	46,490.62	
A C	17,960.18	

/

Related party	Amount for the period	A
H C	1,485,148.52	1,485,148.50
H C	84,905.66	

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(V) Information on related party transactions (Continued)

2. C :

Name of guaranteed party	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
H C ..	14,660,000.00	2019/9/10	2029/3/20	
H C ..	10,230,000.00	2020/1/1	2029/3/20	
H C ..	3,320,000.00	2020/12/22	2029/3/20	
H C ..	2,200,000.00	2020/9/27	2029/3/20	
H C ..	2,200,000.00	2020/9/27	2029/3/20	
H C ..	3,050,000.00	2021/3/1	2029/3/20	
H C ..	3,050,000.00	2021/3/1	2029/3/20	
H C ..	45,000,000.00	2023/7/3	2037/12/31	
H C ..	15,000,000.00	2023/7/31	2037/12/31	
H C ..	10,116,550.00	2023/10/25	2037/12/31	
H C ..	5,007,200.00	2023/11/24	2037/12/31	
H C ..	5,000,000.00	2020/3/25	2024/12/20	
H C ..	17,500,000.00	2020/5/22	2024/12/20	
H C ..	60,000,000.00	2023/10/9	2031/10/9	
H C ..	2,000,000.00	2023/3/31	2024/3/29	
H C ..	26,000,000.00	2023/4/3	2032/3/2	

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(V) Information on related party transactions (Continued)

2. (C)
C :

Name of guarantor	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
H C . .	200,000,000.00		2026/12/24	
H C . .	200,000,000.00		2026/12/24	
C H C . .	200,000,000.00		2026/12/24	
C H C . .	66,474,000.00		2026/12/10	
H C . .	200,000,000.00		2026/12/24	
G H	24,000,000.00	2020/6/30	2027/6/30	
G H ,	79,642,127.25	2021/11/29	2028/11/29	
G H ,	190,950,000.00	2020/10/26	2026/10/25	
G	70,000,000.00	2023/11/8	2026/11/15	
G	135,000,000.00	2023/12/14	2024/12/14	
G H	14,660,000.00	2019/9/10	2029/9/20	
G H	10,290,000.00	2020/1/1	2029/9/20	
G H	3,320,000.00	2020/12/22	2029/9/20	
G H	2,200,000.00	2020/9/27	2029/9/20	
G H	2,200,000.00	2020/9/27	2029/9/20	
G H	3,050,000.00	2021/3/1	2029/9/20	
G H	3,050,000.00	2021/3/1	2029/9/20	
G H	45,000,000.00	2023/7/3	2037/12/31	
G H	15,000,000.00	2023/7/31	2037/12/31	
G H	10,116,550.00	2023/10/25	2037/12/31	
G H	5,007,200.00	2023/11/24	2037/12/31	
G H	5,000,000.00	2020/3/25	2024/12/20	
G H	17,500,000.00	2020/5/22	2024/12/20	
G E				
C C . .	60,000,000.00	2023/10/9	2031/10/9	

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(VI) Receivables from and payables to related parties and other unsettled items

1.

Items	Related parties	Balance as at the end of the period		B	
		Book balance	Provision for bad debts	B	
A	H				
	H C			65,000.00	3,250.00
	H A				
	C	1,522.85	15.23	1,522.85	15.23
	H	635,000.00	6,350.00	635,000.00	6,350.00
	H				
	H C	23,066,977.13	23,066,977.13	34,005,471.02	1,700,273.55
	C	13,903,890.41	695,194.52	14,290,027.40	714,501.37
	C	10,204,311.69	10,204,311.69	10,204,311.69	10,204,311.69
	C	3,490,447.08	3,490,447.08	3,490,447.08	3,490,447.08
	H A				
	C	16,836.66	841.83	16,836.66	841.83
	C	100,000.00	1,000.00	100,000.00	1,000.00
	C	80,004.00	800.04	80,004.00	800.04

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(VI) Receivables from and payables to related parties and other unsettled items (Continued)

2.

		B	
		Book balance	
		as at the end	
		of the period	
Items	Related parties		

Notes to the Financial Statements

F
(A B)

(C)

(VII) Five Individuals with Highest Remunerations

F J 2024, (J 2023: 0),

Items Amount for Totalble:

Notes to the Financial Statements

F 30, 2024
(A B)

(I) Summary of share-based payment

C

1. E I

J 13, 2018, C 2018
H E 2018, B
C B C
G I J 29, 2018, A
20, 2018, C
I
(
) J
) E
) J
)
(
) 2,460,000
B10.47 A D 31, 2021,
C

48 J 2022. A J 30, 2024,
(J 30, 2023:)

Notes to the Financial Statements

F 2024 30, 2024

(A) ☒ ☐ B ☒ ☒ ☐

• (C₂ ~~is~~)

(I) Summary of share-based payment (Continued)

2. H A $\bullet$ $\bullet$ $\boxed{\times}$

101
1.66%
7
52
36
335,000
75,000
1,240,100
364,100
616,000
30, 2024,
A
H
C
J

Notes to the Financial Statements

F
(A B)

I. C

(I) Significant commitments

1. C

	June 30, 2024 D	31, 2023
H , &	55,890,951.92	122,040,000.00
	55,890,951.92	122,040,000.00

2. •

A June 30, 2024, C •

(II) Contingencies

C •

II. E

(I) Profit distribution

B • 2024 (B1.50 () 10 C

Notes to the Financial Statements

F 30, 2024
(A B)

(I) Accounts receivable

1. A 30, 2024

Aging	Balance as at the end of the period	B
1	51,071,471.71	48,552,078.47
1-2	11,406,851.48	257,315.13
2-3	257,315.13	709,878.26
3	4,616,400.13	3,906,521.87
-	67,352,038.45	53,425,793.73
	11,362,291.77	5,359,236.04
	55,989,746.68	48,066,557.69

Notes to the Financial Statements

F 2024 30, 2024
(A B)

(C)

(I) Accounts receivable (Continued)

2. A						B			
Balance as at the end of the period						B			
Book balance						B			
Provision for bad debts						B			
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Carrying amount	A	(%)	A	(%)
11	4,873,715.26	7.24	4,873,715.26	100.00		4,873,715.26	9.12	4,873,715.26	100.00
11	4,873,715.26	7.24	4,873,715.26	100.00		4,873,715.26	9.12	4,873,715.26	100.00
11	57,018,962.00	92.76	6,488,576.51	11.38	50,530,385.49	4,552,074.47	90.88	4,552,074.47	1.00
11	5,459,361.19	8.11			5,459,361.19				
11	57,018,962.00	84.66	6,488,576.51	11.38	50,530,385.49	4,552,074.47	90.88	4,552,074.47	1.00
67,352,038.45	100.00	11,362,291.77			55,989,746.68	53,425,793.73	100.00	5,359,236.04	4,873,715.26
Balance as at the end of the period						B			
Book balance						B			
Provision for bad debts						B			
Proportion of provision (%)						B			
Reason for the provision						B			
Items	Book balance	Provision for bad debts	Proportion of provision (%)	Reason for the provision		B			
11	4,873,715.26	4,873,715.26	100.00	Not expect to be recoverable		4,873,715.26		4,873,715.26	
	4,873,715.26	4,873,715.26				4,873,715.26		4,873,715.26	

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(I) Accounts receivable (Continued)

2. A (C)

1 1 1 1

1 1 1 1

Items	Balance as at the end of the period		
	Accounts receivable	Provision for bad debt	Proportion of provision (%)
1 1 1 1	57,018,962.00	6,488,576.51	11.38
	57,018,962.00	6,488,576.51	

3. 1 1 1 1

Category	B	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
1 1 1 1	4,873,715.26					4,873,715.26
1 1 1 1	4,520.73	6,003,055.73				6,488,576.51
	5,359,236.04	6,003,055.73				11,362,291.77

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(II) Other receivables

Items	Balance as at the end of the period	B
I	787,500.00	
D	14,400,000.00	14,400,000.00
	607,735,083.60	586,043,325.58
	622,922,583.60	600,443,325.58

1. /
I

Items	Balance as at the end of the period	B
	787,500.00	
	787,500.00	

2. D

Item (or investee)	Balance as at the end of the period	B
C H C	4,400,000.00	4,400,000.00
H C	10,000,000.00	10,000,000.00
	14,400,000.00	14,400,000.00

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(II) Other receivables (Continued)

3.
(1) D

Aging	Balance as at the end of the period	B
1	571,062,190.36	552,353,723.97
1 2	5,089,808.65	34,594,797.65
2 3	33,287,580.41	496,167.22
3	1,158,794.57	903,479.96
	610,598,373.99	588,953,173.80
	2,863,290.39	2,304,343.22
	607,735,083.60	586,043,325.53

(2) D

Category	Balance as at the end of the period				B			
	Book balance		Provision for bad debts		B			
	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	(%)	A
	610,598,373.99	100.00	2,863,290.39	0.47	607,735,083.60	588,953,173.80	100.00	2,304,343.22
	80,464,046.88	13.18	2,863,290.39	3.56	77,600,756.49	75,462,763.59	12.92	2,304,343.22
	530,134,327.11	86.82			530,134,327.11	513,390,405.21		
	610,598,373.99	100.00	2,863,290.39	/	607,735,083.60	588,953,173.80	100.00	2,304,343.22

Notes to the Financial Statements

F 2024 30, 2024
(A B)

(C)

(II) Other receivables (Continued)

3. (C)

(2) D 2024 2024 (C)
2024 2024
I 2024 2024

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
A 2024 2024	80,464,046.88	2,863,290.39	3.56
A 2024 2024	530,134,327.11		
	610,598,373.99	2,863,290.39	

Fri Jun 30, 2024

(A ☒) B ☒ ☒)

(II) Other receivables (Continued)

$$(3) \quad D \quad \gamma \quad \gamma \gamma \quad \dots$$

	Stage I	Stage II	Stage III	Total
Provision for bad debts	12-month ECL	Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
B				
	2,804,343.22			2,804,343.22
B				
-				
-				
-				
-				
A	53,442.17			53,442.17
B	2,863,290.39			2,863,290.39

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(II) Other receivables (Continued)

3. (C)

(3) D (C)

C :

	Stage I	Stage II	Stage III	
		Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	Total
B	12-month ECL			
B				
1	588,853,173.80			588,853,173.80
B				
/				
-				
-				
-				
-				
A	21,745,200.19			21,745,200.19
D				
B	610,598,373.99			610,598,373.99

Fri, Jun 30, 2024

(A ☒ B ☒ ☒)

(II) Other receivables (Continued)

(4) $\gamma \gamma$ $\bullet \bullet$ $\eta \bullet$, $\bullet$ $\bullet \gamma$ $\not\Box$ $\gamma \bullet$

Nature of receivables	Book balance as at the end of the period	B
A 100	530,134,327.11	513,390,405.21
25,957,550.96	20,450,175.04	
D 5,716,830.00	5,920,030.00	
181,832.86	767,065.13	
A 100	48,607,833.06	48,295,493.42
	610,598,373.99	533,563,173.80

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(III) Long-term equity investments

Items	Balance as at the end of the period			B	
	Book balance	Provision for impairment	Book value	B	B
I	698,830,684.03		698,830,684.03	691,561,513.66	691,561,513.66
I	94,549,945.13		94,549,945.13	94,421,925.51	94,421,925.51

(III) Long-term equity investments (Continued)

[illegible]

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(IV) Revenue and cost of sales

1. .

Items	Amount for the current period		A	
	Revenue	Cost		C
185,247,902.83	130,785,130.41	174,575,542.75	130,785,397.79	
7,845,218.13		1,629,256.25		
193,093,120.96	130,785,130.41	176,204,799.00	130,785,397.79	

B :

Items	Amount for the current period		A	
185,247,902.83		174,575,542.75		
185,247,902.83		174,575,542.75		
7,845,218.13		1,629,256.25		
6,472,852.67				
209,955.19		512,200.25		
1,162,410.27		1,117,055.97		
193,093,120.96		176,204,799.00		

2. D

Item	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
A			D			
B						

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(V) Investment income

Items				Amount for the current period	A B
I					
				14,061,318.98	
I				128,019.62	16,165.55
I					-1,591,713.27
				14,189,338.60	-775,547.72

2

(

)

2

C

3



Definitions

精神科門診及門診 H 門診	精神科門診及門診 H 門診 (寧) C . . . (寧心理互聯網醫院(溫州)有限公司), C C 10, 2020, C 寧
寧 寧 H 門診	寧 寧 H 門診 C (嘉康寧醫院有限公司), C D 12, 2012, C 寧
寧 寧 H 門診	寧 寧 H 門診 C (清康寧醫院有限公司), C 3, 2013, C 寧
寧 寧 H 門診	寧 寧 寧 I C H 門診 C (清怡寧中西醫結合醫院有限公司), C C A 寧 4, 2006, C 寧 寧 寧 B C & H 門診 (清邦爾中西醫結合醫院有限公司)
%	寧

